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 This dissertation research consists of three investigations in an effort to 
determine how circulating estrogens affect skeletal muscle lipid metabolism.  
Loss of circulating estrogens results in significant increases in visceral fat mass 
and intramuscular lipids (IMCL).  These increases in lipid storage are strongly 
associated with an elevated risk of developing type 2 diabetes.  The first 
investigation examined how the loss of circulating estrogens alters skeletal muscle 
metabolic function.  Ovariectomy (OVX) resulted in significantly higher visceral 
fat mass and fatty acid sarcolemmal transporter content, which corresponded with 
elevated IMCL.  Skeletal muscle in the OVX group exhibited lower acyl carnitine 
species suggesting impaired lipid flux through the mitochondria.  Lastly, 
mitochondrial oxygen consumption rates were impaired in OVX skeletal muscle 
fibers.  The results from this study gave rise to a search to identify an estrogen-
sensitive mechanism that regulated lipid transport into the mitochondria.  Study 
two determined for the first time that the BRCA1 protein, which is encoded by an 
estrogen-sensitive gene, is present and functions as an integral regulator of lipid 
metabolism in skeletal muscle.  Specifically, BRCA1 binds to acetyl CoA 
carboxylase in response to acute exercise.  The in vitro induction of decreases in 
BRCA1 expression resulted in higher IMCL content, reduced mitochondrial 
oxygen consumption rates, and elevated reactive oxygen species production.  
Surprisingly, no differences in BRCA1 content were detected between males and 
females.  In the final study, an inducible, skeletal-muscle specific, BRCA1 KO 
mouse was developed.  Ablation of BRCA1 in skeletal muscle resulted in exercise 
intolerance and the development of kyphosis.  Contrary to our hypothesis, loss of 
functional BRCA1 in skeletal muscle attenuated the negative metabolic 
consequences of chronic high fat diet exposure.  Collectively, these data provide 
strong rationale that BRCA1 is an important regulator of skeletal muscle 
metabolic function and further provide evidence that BRCA1 function is critical 
in multiple tissues across the body.   
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CHAPTER 1: Introduction and Specific Aims 
 Obesity is currently at epidemic proportions in the United States and is 
associated with 300,000 deaths annually (58).  Women constitute a substantial 
portion of the current obesity statistics with 62% of the female population being 
overweight (BMI!25) or obese (BMI ! 30) (71, 74, 125).  It is well established 
that there are differences in body fat distribution and body fat percentages 
between men and women with men partitioning fats to the abdominal region 
(android shape) and women apportioning and storing fats in the hip and thigh 
region (gynoid shape) (36).  The underlying scientific rational as to why fat 
storage differs between sexes is largely undefined.  In post-menopausal women, 
loss of circulating ovarian hormones, predominantly estrogens, results in a 
transition from the gynoid to the android shape as well as an overall percent 
increase in body fat.  These results suggest that female sex hormones are a key 
regulator of fat partitioning, storage and utilization (9, 64).  Therefore, it is no 
surprise that according to the Center for Disease Control (CDC) the highest 
percentage of obese women are post-menopausal (48%).  Further, in response to 
treatments for estrogen positive cancers women are susceptible to visceral obesity 
due to use of anti-estrogen therapies (119).  Since the loss of estrogen signaling, 
regardless of the mechanism, collectively results in visceral obesity it is evident 
that estrogens function as a potent lipid metabolism and fat storage regulator.  
During low to moderate exercise intensities women oxidize lipids at a 
higher rate than men (198, 200).  However, the additional lipids utilized by 
women during exercise are thought to be predominately derived from 
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intramuscular tricylglycerides (IMTG) as opposed to enhanced adipose tissue 
lipolysis (198, 200).  Similar to the athletes" paradox, IMTG stores are higher in 
women than men (13, 21).  However, loss of circulating estrogens results in 
further accumulation of IMTG, which is associated with insulin resistance and 
visceral adiposity (97, 117).  Exercise training decreases IMTG in ovariectomized 
animals (OVX) but not to the level of sedentary ovary-intact animals, again 
implicating estrogens as a key regulator of muscle lipid metabolism (99, 117). 
Despite the considerable amount of evidence implicating the regulatory role of 
estrogens in lipid metabolism, no definitive estrogen sensitive targets have been 
identified in skeletal muscle.  Further, the nation-wide clinical trial termed the 
‘Women’s Health Initiative’ (WHI) suggested that estrogen therapy in post-
menopausal women may have some negative health consequences (224).  As a 
result, there is a need to identify novel estrogen sensitive mechanisms to treat the 
metabolic conditions associated with a loss of circulating estrogens.  Therefore, 
the overall initial aim of my dissertation work was to identify a key 
mechanism responsible for the estrogen-associated differences in skeletal 
muscle lipid metabolism.  The initial investigation assessed the effects of loss of 
circulating estrogens on skeletal muscle lipid metabolism.  Next, this work 
determined the importance of an estrogen sensitive target, breast cancer type 1 
susceptibility protein (BRCA1) in skeletal muscle lipid metabolism and 
characterized the associated intracellular mechanism.    
Specific Aim 1: To determine the impact of ovariectomy on skeletal muscle 
lipid metabolism.   
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 This study determined the consequences of ovariectomy on skeletal 
muscle lipid metabolism.  We found that loss of circulating estrogens in an OVX 
mouse resulted in a substantial increase in visceral fat mass and a significant 
increase in intramuscular lipids (IMCL) which was associated with an increase in 
fatty acid sarcolemmal transporters CD36/FAT and FABPpm.  Using a 
comprehensive metabolic profiling approach we identified differences in the 
skeletal muscle kreb’s cycle intermediates, acyl-carnitines, and amino acid 
content in OVX animals compared to SHAM.  Specifically, the metabolic profile 
revealed significant decreases in acyl carnitine species suggesting that lipid flux 
through the mitochondria was impaired in response to ovariectomy.  Lastly, we 
detected differences in palmitate- and pyruvate-stimulated mitochondrial oxygen 
consumption rates in OVX single muscle fibers compared to SHAM.  In 
conclusion, we determined that the increase in IMCLs is, in part, due to impaired 
fatty acid entry and utilization by the mitochondria (97).  These results gave rise 
to a search to identify an estrogen sensitive mechanism responsible for regulating 
lipid transport into the mitochondria and, thus mediating the aforementioned 
skeletal muscle changes.  Aims 2 and 3 of this proposal were therefore, derived 
from the results of this study.   
Specific Aim 2: To determine if BRCA1 is present and functions as an 
integral regulator of lipid oxidation in female skeletal muscle through its 
interaction with phosphorylated acetyl CoA carboxylase. 
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Breast cancer type 1 susceptibility protein (BRCA1) (BRCA1:human 
protein; Brca1:mouse protein) is produced from the estrogen sensitive gene, 
breast cancer 1 early onset (BRCA1) (BRCA1:human gene; Brca1:mouse gene).  
BRCA1 is commonly recognized as an estrogen sensitive human tumor suppressor 
gene because of the corresponding proteins ability to regulate the cell cycle in 
mammary and other reproductive cells (142, 211).  More recently, BRCA1 was 
identified as a regulator of lipid metabolism in MCF7 breast cancer cells through 
its interaction and preservation of the phosphorylated form of acetyl CoA 
carboxylase (ACC) (126, 148).  While phosphorylated, ACC is inactive resulting 
in reduced production of malonyl CoA (MaCoA), an allosteric inhibitor of 
carnitine palmitoyl transferase-1 (CPT-1) (213).  By reducing MaCoA levels, 
CPT-1 activity increases, facilitating entry of lipids into the mitochondria where 
they undergo #-oxidation (140, 160, 213).  It is well established that acute 
exercise induces phosphorylation of ACC and a reduction in malonyl-CoA levels 
in skeletal muscle, thus promoting lipid oxidation in response to the exercise bout 
(44, 140).  Collectively, the data suggest that if BRCA1 is expressed in skeletal 
muscle, it could be an estrogen sensitive target that regulates lipid metabolism.   
The purpose of this translational study was to 1) identify if BRCA1 was 
expressed in skeletal muscle and if BRCA1 is differentially expressed between 
males and females 2) to determine if the BRCA1 protein interacts with the 
phosphorylated form of ACC in both mice and humans, and 3) to determine if this 
potential interaction enhanced lipid utilization by the mitochondria.  In this 
completed study BRCA1 levels were detected in skeletal muscle and BRCA1 was 
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assessed across different muscle groups from the mouse at both the mRNA and 
protein levels.  Further, BRCA1 levels were compared across male, and female 
mouse skeletal muscle.  In addition, the BRCA1 ACC-p native protein-protein 
interaction was measured in response to an acute bout of treadmill exercise in 
mice.  These findings were also translated to human skeletal muscle where 
mRNA expression of all known isoforms of BRCA1 (BRCA1 total) was 
collectively measured and the 2 short isoforms (BRCA1!11, BRCA1!11b) were 
measured independently in sedentary male and female skeletal muscle.  Similar to 
the mouse portion of this study, we measured total BRCA1 protein levels, and the 
BRCA1 ACC-p protein interaction in response to an acute bout of exercise in 
both male and female human skeletal muscle.  Surprisingly, with the exception of 
BRCA1$11 protein in mouse skeletal muscle, no sex differences were detected in 
mRNA or protein levels or in the BRCA1 ACC-p protein interaction in either 
mouse or human skeletal muscle.  However, there was a significant increase in 
BRCA1 bound to the ACC-p after the exercise bout in both mouse and human 
skeletal muscle.  Despite no differences in sex, the results still demonstrate a 
protein-protein interaction between BRCA1 and ACC-p, implicating BRCA1 as a 
novel and likely integral regulator of lipid metabolism in skeletal muscle.   
Lastly, reductions in BRCA1 (BRCA1total, BRCA1!11, and BRCA1!11b) 
expression human primary myotubes using an shRNA approach resulted in 
elevated IMCL content in control and palmitate/oleate treated myotubes.  In order 
to determine if this effect was due to reduced mitochondrial function, 
mitochondrial oxygen consumption rates (OCR) were measured in control and 
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BRCA1 reduced human myotubes.  Here we determined that in human myotubes 
with reduced BRCA1 content mitochondrial OCR were decreased in the basal, 
uncoupled, and palmitate stimulated states compared to control.  To assess if the 
decreased OCR rates in human myotubes with reduced BRCA1 expression was 
associated with a reduction in phosphorylation of ACC, ACC-p protein levels 
were measured in control and BRCA1 shRNA human myotubes.  Surprisingly, a 
decrease in BRCA1 expression in human myotubes resulted in increased ACC-p 
levels in basal BRCA1 shRNA transduced human myotubes.  Elevated ACC-p 
levels in BRCA1 shRNA were found to be the result of chronic elevation of 
AMPK-p due to increased ROS production by the mitochondria. These data 
collectively indicate that a decline in BRCA1 levels results in a reduced ability to 
actively induce phosphorylation of ACC, coupled with a decline in human 
myotube mitochondrial function. Based on our observations to date we conclude 
that i) BRCA1 is constitutively expressed in skeletal muscle regardless of sex 
or species, ii) an acute bout of exercise increases the BRCA1 p-ACC 
interaction, iii) reducing BRCA1 levels decreases ACC phosphorylation likely 
impairing lipid entry into the mitochondria, iv) reducing BRCA1 levels in 
human myotubes impairs mitochondrial function.  
Specific Aim 3: To determine if Brca1 is required to maintain optimal 
skeletal muscle lipid metabolism during exercise using an inducible, skeletal 
muscle specific, in vivo, loss of function approach.   
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 Following the completion of study 2 in this proposal, the next phase of this 
investigation was to fully characterize the importance of Brca1 in skeletal muscle 
through an inducible, in vivo loss of functional Brca1 in skeletal muscle.  In study 
2, an in vitro model was used to examine the effects of reduced BRCA1 
expression in primary cultured human myotubes.  Unfortunately, this in vitro 
approach does not allow full recapitulation of the physiological importance of 
BRCA1 to skeletal muscle.  For example, it is not possible to measure force 
production in a cell culture model with reduced BRCA1 levels, or assess the 
responses of the cells to acute exercise.  To address these limitations, an animal 
model lacking Brca1 in skeletal muscle is required.  Due to the critical role of 
Brca1 as a cell cycle regulator, it is impossible to utilize a standard, whole body, 
knockout approach due to embryonic lethality.  Therefore, a Cre-Lox breeding 
system was implemented to generate a mouse model of ablated Brca1 expression 
(see methods for detailed description) (48, 56).  To avoid any effects on 
developing skeletal muscle, my animal model utilizes an inducible approach to 
ablate Brca1 expression in an age-controlled fashion.  The following groups were 
used to address all three proposed hypotheses.  The groups consisted of two 
control-injected groups (WT) and two tamoxifen treated groups (KO).  Within 
those groups one group was fed a high fat diet (HFD) while the other was fed a 
control diet (CD).  This animal model was employed to specifically investigate 
the following hypothesis. 
Hypothesis I: Loss of a functional Brca1 protein will impair exercise 
tolerance and increase the onset of muscle fatigue.  
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Exercise Tolerance and Skeletal Muscle Function 
 Although Brca1 is expressed in skeletal muscle its functional role remains 
poorly defined.  Therefore, the following experiments were designed to assess the 
impact of Brca1 on overall exercise performance and skeletal muscle function.  
Specific experiments to determine in vivo running capacity and in situ skeletal 
muscle contractile function were conducted by subjecting animals from each 
group to an acute bout of treadmill exercise as previously described (177).  The 
primary outcome was to determine whether or not a loss of Brca1 on skeletal 
muscle impairs exercise performance.  In order to assess the effects of loss of 
Brca1 in skeletal muscle function in situ electrical stimulation of the 
gastrocnemius muscle group was performed as previously described (219).  Here 
the gastrocnemius group of one limb was electrically stimulated and force 
production was measured while the opposite limb served as an internal control.  
Peak twitch force, peak tetanic force, force-frequency curve and fatigue resistance 
were assessed as previously described (219).  Fatigued and the control 
contralateral gastrocnemius muscle groups were immediately removed, weighed, 
and frozen.   
Hypothesis II: Loss of Brca1 in skeletal muscle will result in reduced 
phosphorylation of Acc in response to repetitive muscle contraction. 
Skeletal muscle Acc-p protein content, Brca1 protein content, Brca1 Acc-p 
protein interaction & Acc activity: 
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The importance of Brca1 in maintaining phosphorylation of Acc in 
response to exercise and the resulting affect on Acc activity has yet to be clearly 
elucidated.  Therefore, the following experiments were designed to evaluate the 
significance of Brca1 in Acc phosphorylation and activity in response to skeletal 
muscle contraction.  To conduct these experiments, gastrocnemius muscles 
removed from the animal upon completion of in situ stimulation and were used 
for the aforementioned biochemical measures.  The contralateral limb served as 
the control.  Specifically, Acc-p was assessed via western blot analysis as 
described in methods.  Similar to investigation 2 of this proposal the native 
protein-protein interaction between Acc-p and Brca1 was evaluated using 
immunoprecipitation and western blotting methods (for details see methods 
section of study 2 manuscript, Appendix 2).  As a surrogate to measuring Acc 
activity, MaCoA levels will be measured in both the contralateral and repetitively 
stimulated skeletal muscle from all groups as previously described (219).  
Hypothesis III.  Loss of Brca1 in skeletal muscle will result in lower lipid 
utilization by the mitochondria, higher IMCL stores and reduced skeletal 
muscle insulin sensitivity.  
Intramuscular Lipid Accumulation: 
We anticipated that if a loss of Brca1 were impairing skeletal muscle lipid 
utilization by the mitochondria, skeletal muscle IMCL accumulation would be 
elevated compared to control animals.  Therefore, IMCL was measured in WT 
and KO animals on CD or HFD, using the neutral lipid fluorescent stain, 
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BODIPY as previously described (97, 198).  Specifically, cross sections from the 
tibialis anterior (TA) muscle was used to detect skeletal muscle lipid 
accumulation as a result of loss of Brca1 as previously described (97).  
Glucose & Insulin tolerance testing: 
 Due to the established relationship between skeletal muscle lipid content 
and the development of peripheral insulin resistance, it is possible that KO 
animals could have exhibited an increased susceptibility to the development of 
insulin resistance.  To address this issue, glucose tolerance tests (GTT) and insulin 
tolerance tests (ITT) were performed on KO and WT animals after consumption 
of either CD or HFD for 10 weeks as previously described (98, 218).  
Isolated Mitochondrial Respiration Measures: 
 Lastly, to analyze the effects of loss of Brca1 on skeletal muscle 
mitochondrial function basal, palmitate, FCCP (uncoupled) mitochondrial oxygen 
consumption rates (OCR) were recorded from isolated mitochondria.  
Mitochondria were isolated from the quadriceps muscles using a modified version 
of the previously described technique (59).  These measures were recorded from 
both the HFD and CD fed animals with and without functional Brca1 as 
previously described using a oxytherm (65).  Collectively these data were used to 
detect alterations in lipid utilization and metabolism within skeletal muscle due to 
loss of Brca1. 
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CHAPTER 2:  
REVIEW OF LITERATURE 
 Obesity has surged to epidemic proportions in the United States of 
America as well as in several other countries throughout the world.  Current 
obesity statistics provided by the U.S. Center for Disease Control (CDC) indicate 
that approximately 35% of adults in the U.S. or 78 million individuals are obese.  
Further, this epidemic also affects children and adolescents with approximately 
15% being obese.  It is well established that obesity contributes to multiple 
deleterious health consequences leading to shortened life span and increases in 
direct and indirect health care costs (39, 157).  Specifically, direct costs are due to 
the cost of preventative, diagnostic and treatment services (57, 221, 222).  Indirect 
costs include costs related to morbidity and mortality as a result of being 
overweight or obese (57, 221, 222).  In total, direct and indirect costs of obesity in 
the U.S. were a staggering $147 billion dollars in 2008 (57).  In addition to the 
economic impact, obesity directly contributes to a decline in life expectancy.  For 
the first time since the onset of recognized “modern medicine” today’s children 
are not expected to exceed the average lifespan of their parents, and the current 
obesity epidemic is likely responsible (111).  According to the CDC obese 
individuals are more likely to develop metabolic dysfunction (type 2 diabetes, 
metabolic syndrome), various types of cancer, and are at an increased risk for 
coronary heart disease, stroke, hypertension, dyslipidemia, sleep apnea, 
respiratory problems, osteoarthritis, mental health conditions, and infertility.  
! "#!
Collectively, it is no surprise that given the current obesity statistics the predicted 
lifespan is decreased. 
The obesity epidemic is mainly attributed to a combination of lifestyle 
and genetic factors, however sex hormone function is also a critical 
consideration. It is well established that differences in body fat distribution and 
body fat percentages exist between men and women.  Men preferentially partition 
fat to the abdominal region (android shape) and women partition fat in the hip and 
thigh region (gynoid shape) (36).  However, in women, a loss of circulating 
ovarian hormones, specifically estrogens, results in a transition from the gynoid 
appearance to the android appearance as well as an overall percent increase in 
body fat (9, 64).   Current obesity statistics indicate that 62% of women are 
overweight (BMI!25) or obese (BMI ! 30) (58), with the highest percentage of 
obese women being post-menopausal (48%).  Consequences of menopause 
include the development of the metabolic syndrome which is commonly defined 
by a combination of disorders including increases in visceral fat mass, coupled 
with dyslipidemia, elevated fasting glucose, and/or high blood pressure (32).  In 
addition, women who undergo therapy for estrogen positive cancers are also 
susceptible to visceral obesity due to use of anti-estrogen therapies (119).  
Surgically induced oophorectomy and premature ovarian failure also results in 
loss of circulating ovarian hormones corresponding with metabolic consequences 
identical to those resulting from age induced menopause.  Therefore, the loss of 
ovarian hormones leading to reduced estrogen function results in a significant 
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increase in obesity risk indicating that estrogens are key regulators of fat 
partitioning in women.  
WHOLE BODY METABOLIC FUNCTION: THE EFFECTS OF 
ESTROGENS AND OBESITY.  
 Metabolic flexibility is impaired in obese individuals.  Metabolic 
flexibility is determined by two specific criteria: 1) insulin can stimulate glucose 
uptake and suppress lipid oxidation during a fed state, and 2) during a fasted state 
an individual can rely on lipids as a primary source of energy (63).  Thus, 
metabolic flexibility describes the ability of an individual to switch between 
carbohydrates and lipid as an energy source.  Metabolic flexibility is commonly 
assessed using respiratory quotient (RQ), which is derived as the ratio of CO2 
expired to O2 consumed.  Lower RQ values (%0.7) indicate more reliance on lipid 
metabolism whereas moderate values indicate a mix of lipid and carbohydrate 
(0.7-1.0) and high values suggest almost exclusive contribution from 
carbohydrate metabolism (1.0) (94, 95).  Metabolic flexibility is impaired in obese 
individuals due to both a decline in insulin stimulated glucose uptake and a 
decrease in lipid oxidation in the fasted state (40, 63).  The onset of metabolic 
inflexibility is a preceding factor to the development of insulin resistance and 
ultimately type 2 diabetes (40, 63). 
Estrogens influence metabolic flexibility.  Estrogens have a powerful 
influence on carbohydrate and lipid utilization by peripheral tissue, thereby 
significantly affecting metabolic flexibility in women 1(28).  The flexibility effect 
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is the result of women maintaining both greater insulin sensitivity as well as 
having a greater capacity to oxidize lipid compared to men (90).  As a result, 
women exhibit a greater difference in RQ from a fasted to a fed state compared to 
men (28).  However, metabolic flexibility in women is impaired in response to 
loss of circulating estrogens, thus increasing the risk for the development of type 
2 diabetes and the metabolic syndrome (28).  The observed decline in metabolic 
flexibility in response to loss of circulating estrogens is attributed to a decline in 
skeletal muscle enzymes associated with insulin stimulated glucose uptake as well 
as a decrease in skeletal muscle lipid oxidation enzymes (28).  Unfortunately, the 
mechanisms by which estrogens influence metabolic flexibility remain poorly 
defined and thus there remains a critical gap in our understanding of the 
regulation of metabolic function in women.  
CELLULAR MECHANISMS THAT REGULATE SKELETAL MUSCLE 
LIPID METABOLISM: 
Skeletal muscle possesses the unique ability to increase metabolic rate 
nearly 100-fold (112).  The ability to increase metabolic rate to such an extent is 
attributed to the unique network of mitochondrial enzymes that allows skeletal 
muscle to utilize lipid as a substrate.  In skeletal muscle, a complex network of 
both identified and unidentified pathways exist, working in a symbiotic 
relationship that allows for lipid uptake from circulation, intramyocellular lipid 
oxidation, and/or intramyocellular lipid storage.  Management of these substrates 
is largely driven by intramyocellular energetic demand and substrate supply.  The 
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following portion of this literature review will discuss the specific mechanisms 
associated with lipid transport from circulation into the intracellular region of 
skeletal muscle.  Next, this literature review will discuss the intracellular lipid 
transport mechanisms through the cytosol, and into the mitochondria where lipids 
undergo #-oxidation.  Lastly, this review will discuss how the aforementioned 
mechanisms are altered as a consequence of obesity and the presence of estrogens 
(see Figure 1&2).  Also, mechanisms responsible for re-esterification of lipids 










tion of a diet rich in omega-3 fatty acids markedly in-
creased FABPc content (43), suggesting that the length
and degree of saturation of the carbon chain of the fatty
acids are important for regulation of FABPc. In agreement
with these findings, in humans the ingestion of a fat-rich
diet in which the ratio of polyunsaturated to saturated
fatty acids was relatively high (0.6) induced a signifi-
cant increase in FABPc protein content in the vastus
lateralis muscle, in contrast to the ingestion of carbo-
hydrate-rich diet for 4 wk (238). It has been suggested
that FABPc cooperates with the membrane-associated
lipid binding protein FAT/CD36 in uptake of LCFA in
cardiac and skeletal muscle (186). Interestingly, in a di-
etary intervention study, a similar increase in FABPc and
FAT/CD36 protein content was observed, in the vastus
lateralis muscle following a fat-rich diet in human volun-
teers in contrast to when a carbohydrate-rich diet was
consumed (238).
Even though exercise training increases the potential
for a higher lipid oxidation, neither FABPc nor ACBP
levels in vastus lateralis muscle in humans were changed
by exercise training, suggesting that the amounts of these
cytosolic proteins were abundant and sufficient in traf-
ficking LCFA-CoA esters and LCFA within the cell during
exercise (155). These data are supported by recent find-
ings in rats showing that endurance training did not affect
the protein level of ACBP in skeletal muscle (74) even
though the lipid oxidation potential in muscle was in-
creased.
D. Metabolism in Mitochondria
Long-chain fatty acyl CoA (LCFA-CoA) is transported
across the mitochondrial membrane for final !-oxidation
to generate acetyl CoA for the tricarboxylic acid (TCA)
cycle. Both transport and oxidation are potential sites of
regulation (Fig. 6).
It has been proposed that an increase in the mito-
chondrial enzymatic activity induced by exercise training
is important for the increased ability of trained muscle to
combust fatty acids during exercise (90). !-Hydroxy acyl
CoA dehydrogenase (HAD) is a key enzyme in !-oxida-
tion. Studies have shown that the activity of this enzyme
is increased in conditions of increased fatty acid flux
other than exercise such as a fat-rich diet (115). In agree-
ment with a role of the enzymatic potential of the muscle
in regulating fatty acid oxidation during exercise, a posi-
tive correlation between maximal LCFA uptake (r ! 0.88,
P " 0.05) or LCFA oxidation (r ! 0.76, P " 0.05) and the
activity of HAD was found across the working thigh (Fig.
7) (146). These findings suggest that the enzymatic capac-
ity in the catabolic pathways is important in determining
LCFA oxidation during exercise, although the exact mo-
lecular mechanism behind this relationship is not clear.
Regulation of LCFA-CoA flow into mitochondria re-
sults from the fact that acyl CoA derivatives cannot pass
the mitochondrial inner membrane directly. First they
have to be converted to their acyl carnitine derivatives.
This reaction is catalyzed by the enzyme carnitine palmi-
toyltransferase 1 (CPT1) present at the outer mitochon-
FIG. 6. Schematic representation of
the likely routes taken for long-chain
fatty acyl CoA (LCFA CoA) to enter the
mitochondrion for subsequent !-oxida-
tion. CPT-1, carnitine palmitoyl trans-
ferase 1; CPT-2, carnitine palmitoyl trans-
ferase 2; ACS, acyl CoA synthetase; TCA,
tricarboxylic acid cycle.
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Figure 2.1. A schematic representation of the mechanisms associated with 
lipid transport from circulation across the sarcolemma and through the 
cytosol to the mitochondria. Circulating lipids and FFAs derived from the 
breakdown of VLDL-TG by LPL are transported across the capillary bed, 
interstitial space and the plasma membrane by multiple fatty acid 
transporters including FAT/CD36, FABPPM, and FATP.  Upon entering the 
cytosolic region FFA are acetylated by ACS resulting in formation of fatty 
acyl CoA.  Fatty acyl CoAs are then transported through the cytosol while 
bound to ACBP and FABPC to the mitochondria (adapted from B. Kiens, 








The delivery of circulating lipid to skeletal muscle occurs in the form of free 
fatty acids (FFA) derived from adipose tissue lipolysis or in the form of 
circulating triglycerides.  Elevations in adipose tissue lipolysis are the result of 
increased #-adrenergic stimulation, which occurs as a result of exercise, fasting 
and/or stress.  In addition to circulating lipids derived from adipose tissue stores, 
triglycerides are hydrolyzed from circulating lipoproteins by the enzyme 
lipoprotein lipase (LPL), providing additional available lipid to skeletal muscle 
(see figure 1).  In contrast to adipose tissue hydrolysis, LPL activity is relatively 
steady with little to no changes associated with increased energetic demand or 
(300) (Fig. 2). Similarly, in the isolated, perfused rat skeletal
muscle, palmitate uptake at rest (298) and during contrac-
tions (299) displayed saturation kinetics when plotted
against the unbound perfusate palmitate concentration. The
studies lend weight to the idea that the arterial concentra-
tion of LCFA to some extent is of importance for extraction
of LCFA in contracting muscle, but it is likely that other
factors inherent in the muscle are of importance too.
FIG. 2. Arterial plasma concentra-
tion (A), fractional uptake (B), uptake
(C), and total oxidation (D) of free fatty
acids (FFA ! long-chain fatty acids)
across the thigh during rest and 3 h of
knee extension exercise in trained and
untrained subjects. Values are means "
SE of 6 subjects in trained and untrained
groups. *P # 0.05 compared with un-
trained; †P # 0.05 compared with previ-
ous value. [From Turcotte et al. (300).]
FIG. 1. Schematic representation of
the likely routes taken by fatty acids from
the capillary to the mitochondria. VLDL,
very-low-density lipoprotein; ALBFA, al-
bumin bound fatty acid; LPL, lipoprotein
lipase; ALBR, albumin receptor; LBP,
lipid binding protein; ACS, acyl CoA syn-
thetase; FABPc, cytosolic fatty acid bind-
ing protein; ACBP, acyl CoA binding pro-
tein; TG, triacylglycerol; LCFA, long-
chain fatty acids; CD36, fatty acid
translocase; FABPpm, membrane fatty
acid binding protein.
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Figure 2.2.  A schematic representation of the mechanisms underlying FFA transport 
into the mitochondria followed by !-oxidation.  Initially, lipids in the form of FFA-
CoA are converted to acylcarnitines by CPT-1.  Acylcarnitines are they shuttled 
across the outer mitochondrial membrane followed by the inner mitochondrial 
membrane by a mitochondrial translocase.  Once across the inner mitochondrial 
membrane acylcarnitine is converted back into FFA-CoA by CPT-1I and undergoes 
!-oxidation (adapted from B. Kiens, Physiological Review, 2006). 
!
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stress (87, 223).  However, LPL enzyme activity is impaired in response to a 
decrease in physical activity, such as in response to limb immobilization (76).  
 In obese individuals with large amounts of visceral fat, circulating lipids 
and VLDL-TG are chronically elevated (185).  Chronic elevation of circulating 
lipids and VLDL-TG is the consequence of increased adipose tissue lipolysis.  
Although circulating VLDL-TG levels are elevated in response to obesity, LPL 
hydrolysis of VLDL-TG is not increased compared to lean individuals (180).  
However, chronically elevated circulating lipids and VLDL-TG corresponds with 
impaired skeletal muscle metabolic function, including a decrease in insulin 
sensitivity, indicating that this mechanism is a clinically important consideration 
in treating obesity. 
 Similar to obese individuals, loss of estrogens as a result of menopause, or 
oophorectomy corresponds with elevated visceral adipose tissue mass and an 
increase in circulating lipids (8, 42).  Specifically, adipocytes isolated from 
adipose tissue of post-menopausal women exhibit enhanced lipolytic rate (43, 
151).  Enhanced lipolytic rate in adipose tissue has also been documented in 
ovariectomized rodent models (218).  Previous research has demonstrated that 
women maintain greater levels of LPL compared to men (101).  Further, loss of 
estrogens has been shown to increase skeletal muscle LPL content in 
ovariectomized rodents (43). These data collectively indicate that loss of 
estrogens results in elevated circulating adipose tissue derived lipids and FFA 
synthesized by LPL hydrolysis of VLDL-TG.   
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Specific protein transporters regulate transport of circulating lipids 
across the sarcolemma into skeletal muscle cells.  Specifically, FFA must 
traverse the endothelium, the interstitial space, and finally the sarcolemma before 
entering the cytosol.  Although specific mechanisms underlying transport of FFA 
through the endothelium and interstitial space are still under debate, three major 
transporters located on the sarcolemmal membrane have been identified.  Fatty 
acid translocase (FAT/CD36), the plasma membrane bound form of fatty acid 
binding protein (FABPPM) and fatty acid transport protein (FATP) are the critical 
regulators of FFA entry into skeletal muscle (17, 25, 26) (see Figure 1).  Each of 
these aforementioned proteins function as integral components in FFA transport, 
however, the mechanism by which FFA transport occurs varies amongst each 
protein.  In addition to the aforementioned protein transporters, recent evidence 
suggests that caveolins, a subclass of lipid rafts, are involved in skeletal muscle 
FFA uptake potentially through an interaction with FAT/CD36 (105).  However, 
no specific mechanism has been elucidated in skeletal muscle.   
FAT/CD36 is an integral plasma membrane protein with two predicted 
transmembrane domains that function to transport FFA from the interstitial space 
into the cytosol (4) (see Figure 1).  The presence of FAT/CD36 has been 
confirmed in both rodent and human skeletal muscle (26, 91, 166).  Further, both 
over expression models and FAT/CD36 null animals models validate the 
importance of FAT/CD36 (55).  Over expression of FAT/CD36 resulted in 
reductions in circulating lipids and a corresponding elevation in FFA oxidation in 
the soleus muscle (91).  In contrast, loss of FAT/CD36 expression resulted in 
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increased circulating lipids as well as reduced fasting blood glucose levels 
indicating impaired lipid oxidation and greater reliance on glucose as a primary 
source of energy (55).  Collectively, these data implicate FAT/CD36 as an 
integral component required for normal FFA transport and metabolism in skeletal 
muscle.   
FABPPM is located on the periphery of the plasma membrane and similar 
to FAT/CD36 also plays an integral role in FFA transport across the plasma 
membrane (see Figure 1).  The function of FABPPM as a FFA transporter in 
skeletal muscle was made apparent when antibody treatment against FABPPM 
resulted in impaired skeletal muscle FFA entry in a dose dependent fashion (176, 
186, 196, 209).  Further, over expression of FABPPM in rat skeletal muscle 
resulted in elevated fatty acid transport in resting muscle (18).  Although it is 
apparent that FABPPM plays an integral role in skeletal muscle FFA uptake and 
metabolism, characterizing the exact mechanism with regards to FFA transport 
across the plasma membrane and into the cytosol is problematic as FABPPM is 
identical to the mitochondrial isoform of the transporter (20, 197).    
The final, commonly recognized skeletal muscle FFA plasma membrane 
protein transporter, FATP1, is an integral membrane protein with six predicted 
transmembrane domains to mobilize circulating FFA across the sarcolemma (see 
Figure 1) (174).  Evidence for the importance of FATP1 in FFA transport is 
largely derived from FATP1 knockout mouse models where loss of FATP1 in 
skeletal muscle resulted in decreased intramuscular triglycerides (IMTGs) and 
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diacylglyclerides (DAGs) storage in response to a high fat diet (103).  However, 
the mechanisms of action of FATP1 in skeletal muscle remain largely 
understudied. 
Elevated circulating lipids, as a consequence of obesity, results in 
increased levels of fatty acid plasma membrane transporters.  Multiple studies 
have shown that humans consuming a high fat diet have higher circulating lipids, 
which corresponds with an increase in FAT/CD36, and FABPPM levels (26, 166).  
In rodents, exposure to a high fat diet results in elevated levels of all three of the 
aforementioned skeletal muscle plasma membrane transporters (101, 192).  
Furthermore, in obese men and women with type 2 diabetes, FAT/CD36 and 
FABPPM levels are greater compared to age matched, lean control subjects (18, 
100). These data collectively demonstrate that elevated circulating FFA, due to 
high fat diet or in obese individuals, results in increased skeletal muscle FFA 
plasma membrane transporters to promote clearance of lipids from circulation.   
Women express higher levels of plasma membrane FFA transporters 
than age-matched men (33, 34).  Specifically, women maintain greater basal 
levels of FAT/CD36 protein and gene expression suggesting that women also 
maintain a greater basal capacity to uptake FFA from circulation compared to 
men (101, 192). In contrast, exercise training increases FABPPM content in men 
but not in women (101).  The training induced increase in FABPPM is the 
consequence of adaptations in men that improve lipid transport capacity to the 
same extent as is observed in females (200).  However, ovariectomy is associated 
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with increases in CD36/FAT and FABPPM protein content in female mice 
suggesting that ability of estrogen to regulate sarcolemmal FFA transport is 
complex and requires further research.  
 Carnitine palmitoyl transferase I (CPT-1) is a critical regulator of 
FFA metabolism in skeletal muscle.  Transport of FFA into the mitochondria is 
an intricate process that requires FFA to cross two mitochondrial membranes (see 
Figure 2).  Specifically, in order to enter the mitochondria, cytosolic FFA-CoA 
obtains a carnitine group via outer mitochondrial membrane (OMM) enzyme 
CPT-1, which then allows FFA-carnitine to cross the OMM and subsequently be 
transferred into the mitochondrial matrix (see Figure 2) (220).  Carnitine 
availability is critical with limited amounts of free cytosolic carnitine reported to 
impair lipid oxidation (102). Transport of acyl-carnitine across the inner 
mitochondrial membrane (IMM) occurs via an IMM translocase (see Figure 2).  
Upon traversing the IMM acyl-carnitine is converted back to FFA-CoA by 
carnitine palmitoyl transferase-II (CPT-1I) and undergoes #-oxidation (220).  
Mitochondrial lipid transport and oxidation are primarily regulated by energetic 
demands.  However, various forms of feedback inhibition including lack of free 
cytosolic carnitine or accumulation of mitochondrial #-oxidation or TCA cycle 
intermediates regulate this process as well.  
In response to increased energetic demand in skeletal muscle CPT-1 
mediated FFA mitochondrial transport is increased.  In skeletal muscle the 
most potent driver of energetic demand is contraction.  Therefore, the onset of 
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moderate or low intensity exercise increases FFA mitochondrial transport to 
accommodate elevated energetic demands (124).  CPT-1 activity is critical to 
increasing FFA entry and subsequently oxidation of FFA by the mitochondria.  In 
response to exercise, the inhibitory components regulating basal CPT-1 activity 
are reduced, resulting in elevated CPT-1 activity and subsequently, increased #-
oxidation of FFAs (160).   
The increase in CPT-1 activity is largely a response to the enhanced 
utilization of ATP in response to muscle contraction.   Elevations in the 
intracellular AMP:ATP ratio triggering the activation of AMP activated protein 
kinase (AMPK) (31).  Activation of AMPK stimulates lipid entry into the 
mitochondria through phosphorylation and thus inhibition of its substrate Acetyl 
CoA carboxylase (ACC).  ACC when active, converts intracellular acetyl CoA to 
malonyl CoA (MaCoA) (160, 213).  The production of MaCoA both inhibits FFA 
entry into the mitochondria through allosteric inhibition of CPT-1 and serves as a 
substrate in combination with acetyl CoA for lipogenesis in skeletal muscle via 
fatty acid synthase (FAS) (44, 169, 183).   However, in response to AMPK 
activation, ACC phosphorylation results in deactivation of ACC and a subsequent 
decrease in intracellular MaCoA and increased FFA transport into the 
mitochondria (160, 213).  
Obesity impairs skeletal muscle CPT-1 activity and increases ACC 
activity, subsequently decreasing FFA entry into the mitochondria.  As an 
individual’s BMI increases there is a corresponding decline in lipid oxidation in 
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skeletal muscle (104).  Entry of FFA into the mitochondria has previously been 
shown to decrease in response to obesity.  Specifically, skeletal muscle transport 
of FFA into the mitochondria via CPT-1 is impaired in obese compared to lean 
individuals (104).  Further, other studies have demonstrated that skeletal muscle 
ACC activity and MaCoA content is elevated in obese individuals (11).  A 
potential consequence of reduced FFA entry into the mitochondria is re-
esterification of FFAs and subsequently accumulation of IMTG, which is a well-
established corollary of obesity.  Further, loss of ACC function in rodent skeletal 
muscle results in protection against high fat diet induced obesity and diabetes 
indicating the importance of FFA transport into the mitochondria (3).    
In humans, it is well established that estrogens enhance mitochondrial 
FFA oxidation (27, 49, 127, 128, 171, 198, 200, 201).  One mechanism by which 
estrogens enhance mitochondrial FFA oxidation is through increased FFA entry 
into the mitochondria through increased CPT-1 content and activity.  Specifically, 
estrogens increases CPT-1 mRNA expression (61), while a decrease in circulating 
estrogens impairs CPT-1 activity (27).  The decrease in CPT-1 activity found with 
a loss of circulating estrogens is associated with elevated intramuscular lipid 
accumulation, and evidence for decreased flux through #-oxidation (97).  In 
conclusion, loss of circulating estrogens inhibits FFA oxidation through impaired 
FFA transport into the mitochondria via CPT-1 activity.    
Mitochondrial transport of FFA results in increased !-oxidation.  #-oxidation 
of FFA-CoA is a four-step process resulting in the formation of a two-carbon 
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acetyl CoA, which is utilized by the TCA cycle.  The five critical enzymes 
involved in the #-oxidation are: acyl-CoA dehydrogenase, enoyl-CoA hydratase, 
#-Hydroxyacyl-Coa Dehydrogenase (#-HAD), and thiolase (see Figure 2).  In 
response to elevated energetic demand, activity of the enzymes involved in #-
oxidation is increased (199).  Further, exercise training stimulates mitochondrial 
biogenesis, including increases in #-oxidation enzymes and subsequently 
enhanced FFA oxidation (84, 122, 171).   
 Multiple studies have demonstrated that obesity often corresponds with 
reduced capacity for skeletal muscle FFA mitochondrial oxidation (104).  
Previous research has demonstrated that a correlation exists between elevated 
adiposity and a decrease in fatty acid oxidation (104).  Although several 
mechanisms are likely responsible for the decline in mitochondrial FFA oxidation, 
it is clear that it is partially attributed to a decrease in #-oxidation capacity and 
mitochondrial enzyme activity (104, 180).  Specifically, impaired #-HAD and 
citrate synthase activity is associated with the onset of obesity (104).  The decline 
in #-oxidation capacity and mitochondrial enzyme activity indicates that while 
obesity negatively impacts skeletal muscle oxidative capacity it may not be due to 
decreased #-oxidation enzyme content but instead a decline in function.  A 
decrease in #-oxidation function can lead to incomplete oxidation of fatty acids, a 
primary contributor mitochondrial stress, and the development of insulin 
resistance (107).  
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Loss of estrogens decreases CPT-1 content and function.  Previous 
research has reported that loss of circulating estrogens results in a decline in CPT-
1 function (27).  Other studies demonstrate that estradiol supplementation 
increases CPT-1 content in female rodents (29).  These findings suggest that 
decreased mitochondrial transport of FFA associated with loss of circulating 
estrogens may be responsible for reduced lipid utilization.  However, the 
underlying ability of estrogen to regulate FFA transport into the mitochondria is 
yet to be fully elucidated.   
Estrogens enhance mitochondrial !-oxidation enzymes and activity in 
skeletal muscle.  As previously discussed, women inherently maintain greater 
skeletal muscle oxidative capacity compared to men (198).  Although the greater 
oxidative capacity observed in women is due to a variety of factors, mitochondrial 
FFA transport and #-oxidation capacity are likely key contributors to this effect.  
Previous research has demonstrated that increased estrogen exposure increases #-
oxidation enzyme content in skeletal muscle (127, 201).  Further, genetic ablation 
of the estrogen receptor & (ER&) results in impaired mitochondrial lipid oxidation 
(163).  It is however, unclear if the decline in mitochondrial FFA oxidation 
associated with ablation of ER& is due to impairments in mitochondrial FFA 
transport or in the breakdown of FFA through #-oxidation.  Further, the same 
study demonstrated that loss of estrogens decreased #-HAD activity by 20% 
compared to control rodents which corresponded with a significant decline in 
lipid oxidation (27).  Other studies in post menopausal women and 
ovariectomized mouse models have demonstrated that loss of estrogenic effects 
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results in impaired mitochondrial function leading to decreases in FFA oxidation 
in skeletal muscle (1, 97).  In women, estrogens directly impact #-oxidation 
enzyme content suggesting that elevated ability to oxidize FFA is partly due to 
influences of estrogens on mitochondrial enzyme content.   In contrast, decreases 
in estrogens are associated with elevations in IMTG, and an overall increase in fat 
mass in post-menopausal women is, in part the result of impaired FFA oxidation 
(1, 43, 97). These data collectively demonstrate that estrogens function as 
mitochondrial #-oxidation agonists and that loss of estrogens impaired #-
oxidation of FFA due to decreased mitochondrial enzyme content and activity.   
Acetyl CoA, derived from !-oxidation and glycolysis, is shuttled 
through the tricarboxylic acid cycle (TCA cycle) to generate electron donors 
in the form of NADH and FADH2. The TCA cycle is comprised of a series of 
chemical reactions generating energy through the oxidation of acetate (203). 
Specifically, the TCA cycle generates three NADH and one FADH2 molecule for 
every cycle.  Only a single GTP molecule is generated per TCA cycle.  It is 
important to note that the significance of the TCA cycle is not to directly 
synthesize ATP but instead to produce large amounts of NADH and FADH2, 
which are utilized by the electron transport chain (ETC) to synthesize ATP. 
The electron transport chain utilizes electron donors in the electron 
transport chain to generate ATP through energy harnessed from the proton 
gradient.  Specifically, NADH and FADH2 serve as electron donors in the ETC 
where electrons are transferred across the IMM.  The last complex in the ETC, 
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complex V, harnesses the energy derived from protons moving across the IMM to 
phosphorylate an ADP molecule in a process known as oxidative phosphorylation.  
Collectively, the ETC generates molecules of H2O and ATP throughout the 
oxidative phosphorylation process.  
Skeletal muscle electron transport chain activity is decreased as a 
consequence of obesity.  Obesity impairs mitochondrial function, resulting in 
decreases in skeletal muscle citrate synthase, NADH oxidase, and succinate 
oxidase activity (139).  The effects of obesity are even more apparent when 
comparing lean and obese individuals.   Total activity of citrate synthase, NADH 
oxidase, NADH oxidase/citrate synthase and NADH oxidase/#-HAD ratios are 
reduced two to three fold in skeletal muscle biopsies obtained from obese 
individuals (38, 164).  Impairments in these components of the mitochondrial 
function directly correspond with elevations in IMTG observed with elevated 
BMI (79, 104).  Collectively, these marked decreases in activity levels of 
mitochondrial TCA cycle and ETC components correspond with a decline in 
skeletal muscle palmitate oxidation rates in obese compared to lean individuals 
(88, 104).   
Loss of circulating estrogens decreases mitochondrial enzyme content 
and activity.  Loss of estrogens in rodents results in decreased citrate synthase 
activity in skeletal muscle (12, 27).  Previous research has demonstrated that loss 
of circulating estrogens in rodent models results in increased citrate and succinate 
content suggesting reduced flux through the TCA cycle (97).  Further, the loss of 
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circulating estrogens also corresponded with a decrease in skeletal muscle free 
carnitine levels and acetyl-carnitine species, indicative of a decrease in FFA flux 
through the mitochondria (97).  Collectively, the alterations in skeletal muscle 
phenotype associated with loss of circulating estrogens in the aforementioned 
study indicated that the decline in skeletal muscle oxidative capacity associated 
with loss of circulating estrogens is the result of mitochondrial FFA transport as 
opposed to mitochondrial oxidative capacity (97).   
A loss of circulating estrogens impairs skeletal muscle mitochondrial 
function and potentially contributes to development of obesity and associated 
diseases.  However, since the effects of obesity can result in a decline in activity 
of TCA cycle and ETC complex function it is difficult to determine whether the 
effects of loss of estrogens are primary or secondary effect to the associated 
alterations in mitochondrial function.  The interpretation is further complicated by 
that fact that no true estrogen sensitive mechanism has been implicitly identified 
in the mitochondria of skeletal muscle.  
CONSEQUENCES OF IMPAIRED MITOCHONDRIAL FFA OXIDATION 
IN SKELETAL MUSCLE 
Chronic delivery of excessive FFA to skeletal muscle in obese 
individuals results in FFA being shuttled towards esterification rather than 
mitochondrial oxidation.  Under normal circumstances skeletal muscle in lean 
healthy individuals maintains some degree of IMTG content.  Upon entering the 
intracellular region the fate of FFAs is principally oxidation by the mitochondria 
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or esterification resulting in the generation of IMTGs.  Oxidation of FFAs by the 
mitochondria is dependent upon energetic demand, mitochondrial content and the 
oxidative capacity of the mitochondria (62, 89, 210).  Although commonly 
associated with metabolic impairment in obese individuals, IMTGs are imperative 
for metabolic function in skeletal muscle and serve as a critical source of energy 
in response to elevated energetic demand (88, 200).    
Esterification of FFA is a multi step process attaching three single FFA to 
a glycerol backbone.  Specifically, FFA-CoA is converted to lysophosphatidate by 
glycerol-3-phosphate acyl transferase (GPAT) which is the first committed step 
towards the formation of a triglyceride as FFA is added to a glycerol backbone 
(30). Lysophosphatidiate acyltransferase (LPAAT) then converts lysophosatidate 
to phosphatidate with the addition of another cytosolic FFA-CoA (118).  
Phosphatidate is then converted to a DAG by phosphatidate phosphohydrolase 
(PPH-1) and lastly, the final FFA-CoA is added to the DAG by diacylglycerol 
acyltransferase (DGAT) to form a single triacylglycerol (33).  These IMTGs are 
stored intracellularly until substrate demand is elevated in response to an event 
such as prolonged endurance exercise.  Accumulation of IMTG is observed in 
obese individuals where FFA delivery greatly exceeds energetic demand and 
mitochondrial capacity to oxidize lipids (88).  In sedentary obese individuals, 
accumulation of IMTG often correlates with the onset of insulin resistance in 
skeletal muscle suggesting that excess IMTG storage can have negative 
consequences.  However, endurance-trained athletes often exhibit elevated IMTG 
content coupled with normal insulin sensitive but an enhanced ability to oxidize 
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lipid.  A prevailing thought is that the IMTG are an immediate FFA source for the 
mitochondria in response to the energetic demand of exercise and thus any stored 
IMTG has a high rate of turnover.   
Elevated IMTG in obese individuals correlates with increased lipid 
intermediate species that are implicated as lipotoxic contributing to the 
negative association between elevated IMTG and insulin resistance (IR).  
Lipotoxicity is the result of excess FFAs being shuttled towards non-oxidative 
pathways resulting in the synthesis of reactive lipid species that promote 
“metabolically relevant cellular dysfunction” (110).  Thus, chronic delivery of 
excessive amounts of lipid into skeletal muscle coupled with lower rates of fatty 
acid oxidation by the muscle potentially contributes to metabolic disease (100, 
179).  Lipotoxicity is typically defined as the accumulation of lipid intermediates 
such as DAG and ceramides (5, 53, 159).  Specifically, Shulman et al. found that 
elevated skeletal muscle DAG resulted in activation of protein kinase C (PKC) ' 
subsequently inducing phosphorylation of serine residues on insulin receptor 
substrate 1 (IRS-1) and inhibiting stimulation of the insulin signaling pathway 
(108). Further, ceramides are also thought to inhibit insulin stimulated glucose 
uptake via inhibition of IRS-1 and Akt activity (5, 158, 159). However, not all 
findings support lipotoxicity as a mediator of insulin resistance in skeletal muscle. 
 Recent evidence suggests that elevated DAG and ceramides may not be 
directly responsible for impaired insulin resistance in skeletal muscle (207).  For 
example, pharmaceutically induced, acute DAG elevations in rodent skeletal 
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muscle did not impair whole body glucose tolerance (207).  Further, loss of 
malonyl CoA decarboxylase (MCD) which results in reduced mitochondrial fatty 
acid transport protects rodents from high fat diet induced glucose intolerance 
(107).  Currently, the underlying mechanisms associated with lipotoxicity and 
insulin resistance in skeletal muscle are controversial suggesting more research is 
required.  
Greater IMTG content in non-obese endurance athletes does not impair 
insulin stimulated glucose uptake.  Although elevated IMTG is commonly 
associated with impaired metabolic function in skeletal muscle, a well-established 
exception is the elevated IMTGs observed in non-obese endurance trained athletes.  
The ‘athletes paradox’ is characterized by the inverse association between 
elevated IMTG and improved insulin sensitivity (14, 45, 46, 67).  The underlying 
rational accounting for the difference in response to elevated IMTG in healthy 
athletes versus obese individuals is the difference in skeletal muscle oxidative 
capacity (7).  Under circumstances where lipid is relied upon frequently as a 
source of energy, such as during endurance exercise, intracellular mechanisms 
have adapted to store large amounts of lipid and metabolize lipids efficiently (89).   
Thus, a key difference between sedentary obese individuals and athletes is the 
frequent exposure to acute bouts of high energetic demand in the muscle.  In 
sedentary obese individuals lipid overload results in enhanced IMTG storage and 
inefficient mitochondrial oxidation of FFA, while athletes store IMTG while 
maintaining effective FFA/IMTG turnover.  Collectively, elevations in IMTG 
! $#!
content are not inherently debilitating to skeletal muscle metabolic function 
assuming complete oxidative function is maintained preventing mitochondrial 
overload and/or the generation of lipotoxic species that impair metabolic function 
(107).   
Ovarian hormones are associated with greater IMTG content in healthy 
women without impaired insulin stimulated glucose uptake.  In addition to 
non-obese endurance trained athletes, non-obese women present with greater 
IMTG content compared to age and fitness level matched men, yet maintain better 
insulin sensitivity (83, 90).  Greater insulin sensitivity in women was also noted in 
response to lipid infusion, a known, relatively immediate inhibitor of insulin 
stimulated glucose uptake in skeletal muscle (90).  In healthy women, elevated 
IMTG content that does not impair insulin function in skeletal muscle (83).  
However, IMTG accumulation as a consequence of obesity does impair skeletal 
muscle metabolic function in women.  In contrast, estrogens clearly enhance 
oxidative capacity of skeletal muscle through a variety of mechanisms (127, 128, 
198, 200, 201).  Given the role of estrogens as a promoter of mitochondrial 
oxidative capacity in skeletal muscle, a loss of circulating estrogens blunts these 
estrogenic associated effects.  As a result, loss of circulating estrogens results in 
elevated IMTG content corresponding with alterations in mitochondrial function 
and reduced insulin sensitivity in rodents as a consequence of lipotoxicity (97).  
Specifically, in ovariectomized mice insulin stimulated Akt phosphorylation is 
decreased compared to control mice and corresponds with a decrease in skeletal 
muscle glucose uptake (217). Further, previous research has indicated that this 
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effect may be the consequence of impaired mitochondrial FFA transport and/or 
function (98).  It is however critical to mention that the mechanisms underlying 
the aforementioned estrogen regulated mechanisms are not well defined.   
Mitochondrial overload may be responsible for impaired mitochondrial 
function in obese individuals.  Recent evidence has demonstrated that chronic 
fatty acid exposure to the mitochondria results in deleterious metabolic 
consequences due to elevations in complete oxidation of fatty acids.  Incomplete 
oxidation of fatty acids can lead to the overproduction of reactive oxygen species 
(ROS) production which is associated with accumulation of long acylcarnitine 
species (107, 116).  Mitochondrial overload is a consequence of high FFA 
transport into the mitochondria coupled with a low energetic demand.  This 
overload concept has given rise to a novel yet compelling argument discussing the 
advantages or disadvantages of promoting or inhibiting lipid entry into the 
mitochondria.  Specifically, over expression of CPT-1 in skeletal muscle increases 
FFA oxidation and preventing insulin resistance in rodents (22), while loss of 
CPT-1 is associated with exercise intolerance in humans and a decreased ability to 
utilize lipids.  Further, loss of ACC in rodents results in resistance to diet induced 
obesity due to increased CPT-1 activity (3).  However, supplementation with 
carnitine, a limiting substrate for CPT-1 during times of high FFA flux, improves 
#-oxidation and improves insulin sensitivity (5, 7, 107, 158, 159).  In contrast, 
more recent evidence suggests that inhibition of CPT-1, with the antagonist, 
etomoxir resulted in elevated IMTG and DAG content without effecting insulin 
sensitivity in human myotubes (207).  Thus, when examining the evidence it is 
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clear that modulating CPT-1 activity can prevent diet induced insulin resistance 
and potentially obesity.  Unfortunately, it is unclear why increasing or decreasing 
CPT-1 function can have both beneficial and negative effects on skeletal muscle 
insulin resistance.  Additional research is required to better define the mechanisms 
that regulate FFA entry into the mitochondria of skeletal muscle.   
CONCLUSIONS: 
In conclusion, it is evident that lipid metabolism in skeletal muscle is a 
multifactorial process beginning with FFA transport across the plasma membrane 
and continuing through mitochondrial transport and oxidation or storage as IMTG.  
The intracellular lipid transport process is continuously in flux with changes in 
energetic demand or substrate availability altering intracellular lipid-handling 
dynamics.  Given the current obesity status of the human population as well at the 
current trajectory of this disease, it is likely that elucidating novel mechanisms 
involved in skeletal muscle lipid metabolism will be critical to improving the 
human metabolic disease outlook.   
Identifying estrogen-regulated mechanisms that modulate metabolic 
function is critical to for improving women’s health.  Specifically, defining 
mechanisms underlying mitochondrial FFA oxidation are essential to preventing 
metabolic based diseases.  As previously discussed, a debate as to whether 
enhancing lipid transport into the mitochondria improves skeletal muscle 
metabolic function or impairs metabolic function is currently ongoing. Since pre-
menopausal women are generally protected from developing metabolic disease, it 
! $&!
is hypothesized that elucidating the role of estrogens in improved metabolic 
health may provide novel insight into pathways and targets that could be used to 
treat the metabolic consequences of obesity.  Further, due to reduction in the use 
of estrogen therapy in women as a consequence of the controversial results of the 
WHI it is critical to define mechanisms regulating lipid metabolism in women to 
attenuate and/or prevent the development of metabolic disease in post-
menopausal women.  
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Chapter 3: Ectopic lipid deposition and the metabolic profile of skeletal 
muscle in ovariectomized mice. 
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Disruptions of ovarian function in women are associated with increased 
risk of metabolic disease due to dysregulation of peripheral glucose homeostasis 
in skeletal muscle.  Our previous evidence suggests that alterations in skeletal 
muscle lipid metabolism coupled with altered mitochondrial function may also 
develop.  The objective of this study was to use an integrative metabolic approach 
to identify potential areas of dysfunction that develop in skeletal muscle from 
ovariectomized (OVX) female mice compared to age-matched ovary intact adult 
female mice (SHAM).  The OVX mice exhibited significant increases in body 
weight, visceral and inguinal fat mass compared to SHAM mice.  OVX mice also 
had significant increases in skeletal muscle intramyocellular lipids (IMCL) 
compared to the SHAM animals, which corresponded to significant increases in 
the protein content of the fatty acid transporters CD36/FAT and FABPpm.  A 
targeted metabolic profiling approach identified significantly lower levels of 
specific acyl carnitine species and various amino acids in skeletal muscle from 
OVX mice compared to the SHAM animals, suggesting a potential dysfunction in 
lipid and amino acid metabolism, respectively.  Basal and maximal mitochondrial 
oxygen consumption rates were significantly impaired in skeletal muscle fibers 
from OVX mice compared to SHAM animals.  Collectively, these data indicate 
that loss of ovarian function results in increased IMCL storage that is coupled 
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with alterations in mitochondrial function and changes in the skeletal muscle 
metabolic profile. 
Introduction 
It is well established that loss of ovarian function in women is associated 
with an increase in fat mass, primarily in the region of the visceral organs, without 
large changes in overall weight gain (71, 74, 125).  This effect extends to female 
animal models of reduced ovarian function (69, 98, 163).  Unlike diet-induced 
obesity, the accumulation of visceral fat mass after loss of ovarian function is not 
entirely due to alterations in activity level or eating behaviors, and can occur 
independent of age (74).  The accumulation of visceral fat mass is strongly 
associated with multiple deleterious metabolic conditions, including peripheral 
insulin resistance, cardiovascular disease, and the metabolic syndrome in various 
models of menopause (32, 68, 156, 170).   
We previously demonstrated that a decrease in circulating estrogens in 
ovariectomized female mice (OVX) results in an increased basal lipolytic rate of 
visceral fat, and subsequent increases in circulating non-esterified free fatty acids 
(NEFAs) (218). Under these conditions, increases in circulating NEFAs provoke 
an increase in demand for clearance of these moieties from circulation (15, 18, 71, 
74, 125).  Skeletal muscle has the capacity to oxidize or store substantial amounts 
of NEFA and therefore serves as a critical disposal site for circulating NEFAs.  In 
skeletal muscle, NEFAs that do not undergo oxidization are stored as triglyceride 
creating a pool of intramyocellular lipid (IMCL), thus the fate of the NEFA is 
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largely dependent upon skeletal muscle energetic demands (69, 86, 98, 149, 163).  
Although IMCLs do not typically impair skeletal muscle metabolic function, 
excessive accumulation of IMCLs is associated with increased insulin resistance 
of skeletal muscle, due to increases in lipid intermediates and subsequent 
activation of specific inflammatory or stress signaling complexes (73, 74).  Our 
data suggest that under conditions of reduced estrogen function, skeletal muscle 
would be challenged by excess circulating NEFAs, which would potentially affect 
vital metabolic processes within the muscle cell. 
In women, circulating estrogens appear to play a critical role in defining 
the capacity to utilize lipids as a source of energy.  For example, a number of 
publications have found that pre-menopausal women oxidize more lipid than men 
in response to an acute bout of exercise (32, 68, 156, 170, 201). Further, genetic 
ablation of the alpha form of the estrogen receptor (ERKO) results in a significant 
reduction in the ability of mitochondria to oxidize lipid (163, 218).  These data 
support the theory that repetitive, but cyclic, estrogen exposure in women induces 
a metabolic profile that encourages lipid oxidation.  Although largely untested, 
under conditions of reduced ovarian function, it would be predicted that skeletal 
muscle has increased IMCL content.  Indeed, some investigations have suggested 
that reduced estrogen function leads to enhanced triacylglycerol (TAG) storage 
within whole muscle lysates (117, 163).  However, it is unclear if the increased 
TAG is due to increases in extramuscular or intramuscular TAG (i.e. IMCL) 
storage. 
! %"!
The goal of this study was to utilize an integrative metabolic approach to 
identify potential areas of metabolic dysfunction in skeletal muscle under 
conditions of reduced ovarian function. We employed multiple physiological 
approaches coupled with a non-biased, comprehensive, metabolic profiling 
approach in skeletal muscle from aged match female mice with and without 
bilateral OVX to identify potential mechanisms. We hypothesized that a loss of 
ovarian function would result in a metabolic phenotype that would encourage 
increases in intracellular lipid storage in muscle.  Currently, there is a poor 
understanding of changes induced by the removal of this critically important 
endocrine organ (i.e. ovary) in women.  Therefore, it is important that we begin to 
address not only the effects of ovarian hormones on non-reproductive tissue, but 
also consider the effects of absence of ovarian hormone exposure on tissue 
function. The OVX model is critically important for women’s health, in that a 
significant number of women undergo prophylactic removal of their ovaries (i.e. 
oophorectomy) for a variety of clinical reasons (141, 225).  Since the ovary 
cyclically secretes numerous endocrine hormones in addition to estrogens, it is 
critical to recognize that the ovary may play a larger role in regulating peripheral 
tissue function beyond 17#-estradiol (i.e. the dominant form of estrogen in 
circulation).  Further, current literature including 17#-estradiol supplementation 
provides 17#-estradiol at supra-physiological levels and does not mimic the cyclic 
nature of circulating 17#-estradiol.  Some studies using 17#-estradiol 
supplementation also demonstrate that 17#-estradiol does not fully attenuate all 
consequences of the loss of functional ovaries (218).  The experiments described 
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here will hopefully provide critical direction for investigators examining the role 
of female sex steroids in the regulation of metabolic function. 
Methods 
Animals: Prior to beginning this study, all aspects were approved by the 
University of Maryland Institutional Animal Care and Use Committee (IACUC) 
Review Board.  Eight-ten week old virgin female C57/BL6 mice were utilized in 
this study.  The mice were divided into two groups: SHAM and OVX, where 
OVX mice underwent bilateral ovariectomy and the SHAM group was 
anaesthetized but ovaries were left intact.  We have previously shown that OVX 
surgery results in an approximate ~70% reduction in circulating estrogens within 
48 hours (182).  Loss of circulating ovarian hormones due to ovariectomy was 
confirmed in OVX animals by a significant decrease in uterine weights compared 
to SHAM animals (Table 1).   Utilizing uterine mass as indicator of reduced 
estrogen function is employed since most methods for quantifying murine derived 
estrogens are not considered accurate. 
 All mice were housed individually in a standard mouse cage in a 
temperature-controlled room with a 12 hour light/dark cycle and were provided 
with ad libitum access to standard rodent chow (Purina Laboratory Rodent Diet 
5001: 23% protein, 4.5% fat, 6% fiber) and water.  Unlike rats, mice do not 
become hyperphagic in response to ovariectomy and were therefore preferentially 
chosen as the animal model for this study (93, 133, 215).  To confirm this finding, 
food intake was measured in a separate cohort of age-matched animals, as 
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previously described (206).  All tissue was collected 8-10 weeks after the OVX 
surgery. All animals were age-matched and the food was removed 4-5 hrs prior to 
the tissue collection, with the food removed at 05:00 and tissue collected at 
~10:00.  We have previously observed that increases in visceral adiposity and loss 
of regulatory control of lipolytic function occurs at eight weeks post surgery (218).  
Intramyocellular lipid (IMCL) quantification: Lipid droplets (LD) were visualized 
and quantified using BODIPY (493/503) (Invitrogen, CA) as previously described 
by our group (189, 227).  Muscle cross-sections: The soleus and plantaris muscles 
from SHAM and OVX mice were mounted using Tissue-Tek O.C.T. Compound 
(Andwin Scientific, Schaumburg, IL) and sectioned transversely through the mid-
belly of the muscle.  The cross-sections were mounted on glass slides and 
remained at room temperature for 10 mins prior to fixation in 10% 
paraformaldehyde for 5 mins.  Sections were then rinsed 3 times using 1x PBS 
solution and were then exposed to BODIPY 493/503 (1 µg/mL) in 1xPBS for 30 
mins.  Sections were then rinsed 4 times for 10 mins using 1X PBS to remove 
excessive BODIPY stain.  Vectashield (Vector Labs, Burlingame, CA) containing 
DAPI was then placed on each section followed by cover slips.  Sections were 
imaged using a Nikon Eclipse 50i (Nikon Instruments Inc. Melville, NY) at 20x 
and 40x magnification.  Pictures were taken with a Photometrics Coolsnap camera 
(Tucson, AZ) and processed using Image Pro-Express 6.3 software.  Images were 
quantified using Image J (developed by National Institutes of Health) using the 
same criteria previously described for Oil Red O procedures (67).  A total of 50 
fibers were quantified per muscle section. Single muscle fibers: Intact single 
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skeletal muscle fibers were enzymatically isolated from the flexor digitorium 
brevis (FDB) muscle from SHAM and OVX animals.  In brief, surgically excised 
FDB muscles were incubated in dissociation media (DM) containing DMEM 
(Invitrogen), gentamycin (50 (g/ml), FBS (2%, ATCC, #30-2020 Rockville, MD), 
and collagenase A (4 mg/ml, Roche, Indianapolis, IN,) in an incubator (37°C, 5% 
CO2) for 1.5-2 hours.  Following the dissociation, muscles were placed in a new 
35 mm plate with warmed media containing gentamycin and FBS but without 
collagenase. FDB muscles were triturated with a small bore (~ 1mm) fire polished 
glass transfer pipette to yield single FDB myofibers.  Following trituration, large 
debris (nerve, un-digested FDB muscle) was removed with forceps.  The single 
fibers were then placed onto an ECM coated glass bottom plate (MatTek, Ashland, 
MA) according to previously described techniques (14).  Fibers were allowed to 
adhere, rinsed with Ringer buffer to remove all media, and stained for 30 mins 
with BODIPY 493/503 and 4,6-diamidino-2-phenylindole (DAPI) to label 
myonuclei (Invitrogen, Cambridge, MA) (14). After 30 minutes, the dyes were 
removed by rinsing fibers 3X with fresh Ringer buffer.  Fibers were imaged using 
a Zeiss AxioObserver Z1 fluorescent microscope (Carl Zeiss MicroImaging, Jena, 
Germany).   
Immunoblot procedures:  Plantaris muscles were used to determine the protein 
content of CD36/FAT and FATPpm in the SHAM and OVX mice according to 
previously described methods (16).  The soleus muscle was not used because we 
were unable to extract a sufficient amount of total protein to reliably measure the 
CD36/FAT or FATPpm. Muscles were homogenized, proteins separated by SDS-
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PAGE and the transporters were detected through immunoblotting using 
antibodies specific for CD36/FAT or FATPpm as previously described (16).  
Equal quantities of total protein were loaded (20 µg) on each gel and Ponceau S 
staining on the membranes was used to confirm equal loading.   
Mitochondria Isolation and Immunoblot Procedure: Mitochondria were isolated 
from gastrocnemius muscles from SHAM and OVX muscles as previously 
described (59).  Isolated mitochondria were used to determine the protein content 
of mitochondrial enzymes very long chain, long chain, and medium chain acyl 
CoA dehydrogenases (VLCAD, LCAD, MCAD) and mitochondrial complexes I-
V as previously described (98, 113, 129, 162).  Immunoblotting was conducted 
using antibodies specific for VLCAD, LCAD, and MCAD (kindly provided by Dr. 
Jerry Vockley, University of Pittsburgh) and aspects of mitochondrial complexes 
I-V were detected using an antibody cocktail (AbCam, Cambridge, MA.). 
Metabolic Profiling:  All procedures were performed as previously described 
(107).  Briefly, the whole gastrocnemius muscle was isolated from SHAM and 
OVX animals and frozen in liquid nitrogen.  The tissue was ground in a liquid 
nitrogen chilled mortar and pestle, and ~25 mg was suspended in water, 
homogenized on ice, sonicated, and then spun for 15 min at 4°C, 14,000 rpm. 
Data are normalized to the total protein content in each sample, as determined by 
BCA protein assay (Pierce Thermo Fisher Scientific, Austin, TX, USA).  
Measurement of free carnitine, acylcarnitines and amino acids in muscle was 
completed by direct-injection electrospray tandem mass spectrometry (MS/MS), 
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using a Micromass Quattro Micro LC-MS system (Waters-Micromass, Milford, 
MA, USA) equipped with a model HTS-PAL 2777 auto sampler (Leap 
Technologies, Carrboro, NC, USA), a model 1525 HPLC solvent delivery system 
(Agilent Technologies, Palo Alto, CA, USA) and a data system running 
MassLynx 4.0 software (Waters Corporation, Milford, MA) at the Sarah W. 
Stedman Nutrition and Metabolism Center Mass Spectrometry Lab. Organic acids 
in muscle were quantified using methods described previously employing Trace 
Ultra GC coupled to a Trace DSQ MS operating under Excalibur 1.4 (Thermo 
Fisher Scientific, Austin, TX, USA) 
Skeletal Muscle Malonyl CoA Measures: Malonyl CoA measures were performed 
on the skeletal muscle from sedentary SHAM and OVX mice as previously 
described (138).  
Single muscle fiber based microplate respirometry:  Bioenergetic analyses of 
isolated FDB muscle fibers were performed using an XF24-3 Extracellular Flux 
Analyzer (Seahorse Bioscience) as previously described by our group with slight 
modifications (175). After euthanasia, both flexor digitorum brevis (FDB) 
muscles were removed from OVX mice and SHAM animals (n = 3/group).  
Individual fibers were isolated and plated on extracellular matrix (ECM; Sigma 
EW1270, St. Louis, MO) coated V7 microplate (Seahorse Bioscience, Billerica, 
MA) overnight according to our previously described methods (175). After 
calibration of the XF24-3 Extracellular Flux Analyzer, the microplate containing 
the SHAM and OVX single muscle fibers was placed in the analyzer. Basal 
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oxygen consumption rate (OCR, pmoles/min) were initially quantified across both 
groups in assay measurement buffer (MB) at ~37oC contained 120 mM NaCl, 3.5 
mM KCl, 1.3 mM CaCl2, 0.4 mM KH2PO4, 1 mM MgCl2, 5 mM HEPES (pH 
7.4) supplemented with 2.5 mM D-glucose (Sigma G7528) and 0.5 mM L-
carnitine (Sigma CO158).  Mitochondrial respiration was induced with either 
albumin (Roche, Indianapolis, IN, 03117405001) conjugated sodium palmitate 
(Sigma P9767; 50uM) or sodium pyruvate (10 mM, Sigma P8574) and OCR was 
measured.  A second identical treatment of substrate was initiated after 20 mins 
and OCR was again recorded. Following the last OCR measure induced by the 
second exposure of substrate, 400nM carbonyl cyanide 4-(trifluoromethoxy) 
phenylhydrazone (FCCP, Sigma C2920) was injected to induce maximal 
mitochondrial oxygen consumption and OCR was measured.  At the conclusion of 
the last FCCP measure Antimycin A (Sigma A8674; 1 µM), a known inhibitor of 
mitochondrial complex III, was injected to assess non-mitochondrial OCR 
measures. OCR measures presented are the average values detected after the OCR 
reaches a steady state following the introduction of the substrate or FCCP.  Basal 
OCR values presented are taken immediately prior to the first injection of either 
pyruvate or palmitate. The mean derived for each group was determined by 
collecting the average OCR values from 7-10 different wells per muscle from 
each animal.  This results in approximately 25-30 independent measures per 
group as we previously described (28).  The single fibers were seeded so that each 
well is ~60% confluent. 
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Statistics: All data are expressed as means ± SE. Statistical significance was 
determined using a t-test for all measures. A P value of % 0.05 was considered 
significant. 
Results 
Anatomical Characteristics: OVX mice have significantly greater body weight 
compared to age-matched SHAM animals (Table 1).  The OVX mice also 
exhibited significant increases in visceral (omental/mesenteric) and subcutaneous 
(inguinal) fat mass compared to the SHAM mice (Table 3.1).  As expected, 
uterine mass was significantly decreased in OVX mice compared to SHAM mice 
indicating a successful reduction in circulating estrogens (Table 3.1).  OVX mice 
also ate significantly less food per day over the 8 weeks, even though they 
continued to gain body weight (Table 3.2).  When comparing feed efficiency as 
calculated body weight per kcal consumed, the OVX animals had increased 
ability to store energy as body weight (Table 3.2). 
IMCL Accumulation: Based on our previous studies demonstrating that OVX 
animals exhibit significant increases in basal lipolytic rates of visceral fat and 
elevations in circulating NEFA, we sought to determine if OVX mice have 
increased IMCL in their muscle compared to SHAM animals.  IMCL levels were 
significantly elevated in both the soleus and plantaris muscles from the OVX mice 
compared to SHAM mice (Figures 3.1A-B and 3.2A).  In addition, we observed 
IMCL within the single muscle fibers to confirm that the IMCL elevations in the 
muscle from the OVX were due to increased LD frequency within the myoplasm 
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and not between the muscle fibers (Fig 3.2B).  In the SHAM animals, we found 
very few LD within the isolated single muscle fibers (Fig 3.2B). 
Fatty Acid Transporter protein content: Since IMCL content was elevated in the 
OVX groups compared to the SHAM animals, we measured the protein content of 
the two primary sarcolemmal fatty acid transporters in skeletal muscle.  We found 
that both FAT/CD36 (Figure 3.3A) and FABPpm (Figure 3.3B) were significantly 
increased in OVX mice compared to SHAM mice. 
Metabolic Profiling:  Due to the metabolic complexity of skeletal muscle, we 
assessed the metabolic profile of skeletal muscle from OVX animals compared to 
SHAM animals using a targeted metabolomics approach.   The purpose of these 
experiments was to identify potential pathways or targets that could account for 
the metabolic dysfunction that appears in the OVX animals.  These metabolites 
are byproducts of fuel degradation that reflect shifts in substrate availability 
and/or flux limitations at specific catabolic enzymes. 
Acylcarnitine Intermediate Profile: Acylcarnitine species levels were quantified in 
gastrocnemius muscles from the SHAM and OVX groups to assess specific steps 
of #-oxidation. This approach provides the investigator a snapshot of substrate 
flux and can provide the investigator specific experimental direction for 
identifying potential metabolic limitations. For example, high levels of long chain 
acylcarnitines (LC) might suggest that movement of fatty acids via mitochondrial 
Carnitine palmitoyltransferase I (CPT-1) exceeds flux through #-oxidation 
enzymes, such as long-chain (LC) acyl-CoA dehydrogenase and/or # -OH-acyl-
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CoA dehydrogenase (205).  Based on previous results in other models of obesity 
and due to the accumulation of IMCL in the OVX muscles, we hypothesized that 
LC in the muscle from OVX muscles would be elevated compared to the SHAM 
animals (107, 194, 205). Surprisingly, we found total LC species to be reduced in 
the OVX group compared to the SHAM group (Figure 3.4A).  No differences in 
medium chain (MC) acylcarnitines were identified (Figure 3.4B), but we did 
detect significantly lower levels of short chain (SC) acylcarnitines in the OVX 
group compared to the SHAM group (Figure 3.4C).  These data suggest a reduced 
flux through the #-oxidation pathway in the muscle from the OVX group 
compared to the SHAM group.  Coupled with the reduction in acylcarnitines, we 
determined that skeletal muscle free carnitine levels were significantly lower 
(P%0.05) in OVX mice compared to SHAM mice (Figure 3.4D).  A number of 
previous publications have found that a reduction in free carnitine levels 
correlates with decreases in skeletal muscle lipid metabolism (102, 152, 210). 
Collectively, these data imply that reductions in flux through #-oxidation could 
contribute to a decline in skeletal muscle lipid catabolism under conditions of 
reduced estrogenic function.   
Skeletal Muscle Malonyl CoA and CPT-1 Content: The reduced levels of acetyl-
carnitine coupled with the reduced free carnitine content might suggest an 
impaired flux through #-oxidation as a result of reduced fatty acid transport 
through CPT-1.  We measured CPT-1 mRNA levels and detected no differences 
between SHAM and OVX animals (CPT-1/18S: SHAM = 0.881 ± 0.03 vs. OVX 
= 0.0822 ± 0.02).  CPT-1 activity is negatively regulated by allosteric interactions 
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with malonyl CoA, therefore the observed reductions in acylcarnitines in the 
OVX animals could be the result of increased malonyl CoA content (19, 161, 
169).  However, no differences were detected in skeletal muscle malonyl CoA 
content between sedentary SHAM and OVX animals (Figure 3.5).  
Glycolytic and TCA cycle metabolites: Previous data in other models of obesity 
have shown that accumulation of LC-acylcarnitines species was associated with a 
significant reduction in Krebs cycle intermediates, reflecting a form of 
mitochondrial dysfunction. We found no differences in either pyruvate or lactate 
levels between OVX and SHAM animals (Figure 3.6A). However, citrate and 
succinate levels were significantly (P%0.05) higher in skeletal muscle from OVX 
compared to SHAM (Figure 3.6B,D).  Finally, no significant differences were 
detected in TCA cycle intermediates, &-ketogluterate (&KG), fumarate, and malate 
(Figure 3.6C,E).   
Amino acid profile: It is well established that amino acids play an integral role in 
skeletal muscle metabolism by serving as substrates for catabolic and anabolic 
processes that directly contribute to overall function of the muscle.  In addition, 
previous work has shown that the branched chain amino acid (BCAA) profile is a 
potential contributor to insulin resistance in the obese state (150).  Therefore, we 
evaluated the skeletal muscle amino acid profile in the OVX mice compared to 
the SHAM mice (Figure 3.7A-D).  In OVX mice, we identified significant 
decreases in the BCAAs, leucine and isoleucine, however there was no significant 
difference in valine as compared to SHAM mice (P%0.05) (Figure 3.7B,C).  We 
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also found significant decreases in the concentrations of alanine, 
glutamine/glutamic acid, proline, serine, and histidine in OVX mice compared to 
SHAM (Figure 3.7A,B,C).  
Odd Chain Acyl-Carnitine Species: Odd chain acyl-carnitine species 
propionylcarnitine (C3), isovalerylcarnitine (C5), and tiglyl carnitine (C5:1) are 
products of BCAA catabolism (130, 144).  Due to the observed decline in skeletal 
muscle amino acids in OVX mice, we measured C3, C5, and C5:1 species in 
SHAM and OVX mice. We detected a reduction in C3 species in OVX mice 
compared to SHAM (P%0.05) and no difference in C5 species (Figure 3.8). 
However, we observed a reduction in the unsaturated C5:1 acyl-carnitine species 
(P%0.05) (Figure 3.8). No significant differences in hydroxylated odd-chain acyl 
carnitine species ratio C5-OH/C3-OH were detected.  Collectively, these data 
indicate a decline in catabolism of BCAAs and likely a reduced pool of available 
amino acids to the muscle in the OVX condition (144). 
Mitochondrial Oxygen Consumption: To determine if any of these alterations in 
metabolite levels was associated with compromised mitochondrial function, we 
assessed mitochondrial oxygen consumption induced by either palmitate or 
pyruvate in intact single FDB muscle fibers isolated from SHAM and OVX mice.  
The advantage to this approach is that we can assess mitochondrial function with 
no disruption to the integrity of the muscle fiber or the organelle, thereby allowing 
measures to be taken in the most native form of the mitochondria.  Basal OCR 
was significantly lower in fibers isolated from the OVX animals compared to the 
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SHAM animals (Figure 3.9A).  To determine the response to substrate exposure 
we normalized the OCR to the baseline OCR values, since the basal OCR 
measures were different between the SHAM and OVX prior to substrate exposure.  
Palmitate exposure stimulated significant increases in both normalized OCR from 
baseline in SHAM and OVX fibers, with no significant differences between 
groups (Figure 9B). Pyruvate stimulated normalized OCR was increased from 
baseline in both OVX and SHAM, however, there was no significant difference 
between the OVX and SHAM groups (Figure 3.9C).  To assess substrate specific 
maximal ETC activity, we added the uncoupling agent, FCCP, and found 
significant increases in normalized OCR in the OVX and SHAM compared to 
baseline OCR with both palmitate and pyruvate substrates (Figure 3.9B and C).  
However, regardless of substrate, FCCP stimulated normalized OCR were 
significantly lower in the fibers from the OVX group compared to the SHAM 
indicating a potential impairment in electron transport chain function (Figure 
3.9B,C).  Calculation of the spare respiratory capacity (SRC), as previously 
described by our group (175), suggests a reduced ability of mitochondria from the 
OVX fibers compared to SHAM fibers to respond to stimuli that would activate 
mitochondria (Figure 3.9 D,E). 
Mitochondrial Enzyme Content: To determine if our observations of decreased 
long-chain acylcarnitines and diminished FCCP stimulated respiration were due 
to differences in mitochondrial enzyme content, we measured mitochondrial 
enzyme proteins in skeletal muscle from SHAM and OVX mice.  No differences 
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in VLCAD, LCAD, MCAD protein content or ETC mitochondrial protein content 
were observed between SHAM and OVX animals (Figure 3.10).  
Discussion 
Reductions in circulating estrogens in women, due to either the onset of 
age-induced menopause or menopause as a result of ovariectomy, correlate with a 
robust increase in visceral fat mass (71, 74, 125).  Our data demonstrate that 
compared to the SHAM group, OVX mice exhibit increased adiposity that is 
coupled with significant accumulation of IMCL, CD36/FAT and FABPpm protein 
content within the skeletal muscle. To identify potential metabolic mechanisms, 
we employed a metabolic profiling approach in the skeletal muscle from these 
animals.  When comparing data from OVX and SHAM animals, the results 
suggest that reduced substrate flux through #-oxidation in the OVX animals may 
contribute to increased IMCL content. Finally, we determined that there are 
specific deficits in basal and maximal stimulated mitochondrial oxygen 
consumption in single muscle fibers from the OVX animals compared to the 
SHAM that are not explained by reductions in mitochondrial protein content.  
Collectively the data indicate that loss of ovarian function leads to visceral 
adiposity and IMCL accumulation, and our experiments document the metabolic 
profile of skeletal muscle under this condition.  
Consistent with other studies, we found that ovariectomy resulted in 
significant increases in both visceral and subcutaneous fat mass compared to the 
SHAM mice (69, 98).  We previously reported that increases in visceral fat mass 
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in the OVX model are associated with an enhanced lipolytic rate, yielding an 
increase in circulating NEFAs (218) that suggests skeletal muscle in the OVX 
animals is exposed to higher levels of NEFA.  Based on experiments in cultured 
skeletal muscle cells, exposure of the cells to exogenous NEFA results in 
increased IMCL content (114).  OVX mice exhibited significantly more IMCL 
than SHAM animals, which was associated with markedly higher protein content 
of two key fatty acid sarcolemmal transporters FABPpm and FAT/CD36.  
Although other models of obesity have demonstrated similar findings (18, 86), to 
our knowledge this is the first time these increases have been documented in the 
OVX model.  The observed increase in FAT/CD36 and FABPpm in the OVX 
group is likely the result of an enhanced demand for clearance of NEFAs from 
circulation and corresponds with an increase in IMCL deposition into skeletal 
muscle.   
Due to the metabolic complexity of skeletal muscle, we employed a 
targeted metabolic profiling approach to generate a comprehensive non-bias 
analysis of skeletal muscle in the SHAM and OVX groups (107).  Since the OVX 
group exhibited significant increases in adiposity coupled with high IMCL, we 
hypothesized that, in a similar fashion to other obesity models (29,33), we would 
find substantial increases in LC in the OVX group compared to the SHAM group.  
Surprisingly, we found relative decreases in the LC levels in the OVX, which 
could suggest impaired transport of LCFA into the mitochondria.  The enzyme 
CPT-1 combines cytosolic free carnitine with long chain fatty acids, producing an 
acyl-carnitine that is then transported into the mitochondria (22).  CPT-1 activity 
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is reduced through allosteric inhibition by malonyl CoA and a lack of free 
carnitine (81, 102, 210).  Therefore, because we detected no differences in 
malonyl CoA levels or CPT-1 mRNA levels, but did detect a reduction in free 
carnitine levels in the OVX group, we suspect that transport of LCFA into the 
mitochondria via CPT-1 is a potential point of limitation for lipid oxidation under 
conditions of reduced ovarian function.  In agreement with this conclusion, others 
have shown in the OVX rat model that CPT-1 activity in skeletal muscle is 
significantly lower than in SHAM controls (27).   
The observed decline in SC in response to ovariectomy might suggest 
reduced flux of fatty acids through #-oxidation.  This theory is further supported 
by evidence in humans that suggests numerous points in the #-oxidation and other 
lipid metabolism pathways are sensitive to fluctuations in estrogens (61, 127, 201).  
However, we found no differences in the mitochondrial protein content of 
VLCAD, LCAD, or MCAD in the muscle from the SHAM and OVX animals.  
Based on our data it seems critical to measure SCAD as well, however we were 
unable to obtain an antibody specific to murine tissue.  Collectively, these data 
indicate that under conditions of reduced estrogen function, there are critical 
changes that may be affecting flux through #-oxidation and contributing to 
alterations in lipid metabolism. 
Upon entry into the cell, NEFAs are routed either towards re-esterification 
and subsequently synthesized into IMCL, or if energetic demand is elevated, 
shuttled into the mitochondria for oxidation (86).  Our data demonstrate that 
skeletal muscle IMCL is robustly increased in both the plantaris and soleus 
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muscles in the OVX group; suggesting NEFA flux into the muscle is elevated.  To 
determine if alterations in mitochondrial function are contributing to the increased 
IMCL, we measured mitochondrial oxygen consumption (OCR) of intact single 
muscle fibers from SHAM and OVX animals.  Under basal conditions (i.e. low 
glucose), mitochondrial OCR was significantly reduced in the muscle fibers from 
the OVX fibers compared to SHAM fibers.  However, when we added substrate 
(i.e. Pyr or PA) the OCR increased by the same percent in both groups.  These 
findings suggest that under conditions of low energetic demand, skeletal muscle 
mitochondria in the OVX animals respond in similar fashion to SHAM animals to 
increased substrate delivery.  When stimulated with FCCP to induce 
mitochondrial uncoupling, the fibers from the OVX animals demonstrated a 
reduced ability to respond to increased oxygen consumption compared to the 
SHAM animals.  Further, the lower SRC capacity of the fibers from OVX animals 
suggests that mitochondria have a reduced ability to respond to a maximal 
stimulus that would enhance oxidation of metabolic substrates such as lipid or 
glucose.  However, since mitochondria rarely operate in these maximal ranges, it 
seems unlikely that reduced SRC capacity is a limiting factor that explains the 
IMCL accumulation in the OVX model.  Since, the fibers from the OVX animals 
were able to increase their OCR to the same magnitude as the fibers from the 
SHAM animals in response to the PA exposure, it also seems unlikely that the 
mitochondria are the limiting factor to explain the IMCL buildup.  We also 
detected no differences in the protein content of various mitochondrial proteins, 
making it unlikely that a loss of mitochondrial content is a contributing factor.  
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Using FCCP to drive mitochondrial oxygen consumption is a common 
experimental procedure, however it is unclear if lower FCCP-driven OCR rates 
would translate to a measurable physiological deficiency (i.e. reduced exercise 
capacity) in skeletal muscle of the OVX mice.  For example, we have found little 
evidence indicating enhanced in vitro or in situ fatigue development in skeletal 
muscle from OVX animals (219), however it is well documented that OVX 
animals often exhibit poor exercise performance.  Specifically, we and others 
previously reported a decline in voluntary wheel running in OVX animals (69, 98).  
In agreement with our findings, Rogers et al. found a decline in nocturnal 
ambulatory activity levels in OVX mice as well as decreased oxygen consumption 
compared to SHAM (167).  Therefore, the enhanced deposition of IMCL in 
skeletal muscle is not solely a response of reduced mitochondrial function in the 
OVX fibers.  Considering the number of in vitro and in vivo studies showing that 
estrogens influence mitochondrial biogenesis and function in tissues other than 
skeletal muscle (132, 195, 230-232), it remains plausible that optimal 
mitochondrial function in skeletal muscle is influenced by estrogen function 
however it is likely that other unknown factors are contributing to the increased 
IMCL.   
Skeletal muscle amino acid metabolism is not well characterized with 
regards to estrogenic influences.  Recent evidence in other obesity models has 
suggested that elevated concentrations of BCAA are a significant contributor to 
the development of insulin resistance (150).  Surprisingly, we found that 
concentrations of the majority of amino acids were significantly reduced in the 
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OVX group compared to the SHAM groups, with even the non-significant 
differences tending to decrease in the OVX group.  The decreases in amino acid 
levels may suggest enhanced metabolic amino acid catabolism or a loss of the 
available amino acid pool.  The former is a perplexing finding, since we detected 
decreases in odd-chain acetylcarnitine species and our previous research has not 
identified losses in skeletal muscle mass of the OVX animals compared to the 
SHAM animals (218).  However, an accelerated decline in skeletal muscle mass 
has been observed in postmenopausal women (6), which may suggest that if  
OVX animals were allowed to remain in the reduced estrogen condition longer, 
reductions in muscle mass become apparent.  Our data may also suggest there is a 
reduction in the amino acid pool within the muscle of the OVX animals, which 
leads to a reduction in the availability of amino acids for protein translation.  This 
finding may explain previous results in which we and others have shown that 
OVX animals have reduced mTOR signaling response coupled with lower muscle 
growth with loading of the skeletal muscle compared to SHAM animals (136, 
182).  However, this hypothesis would need to be further tested. 
Potential Limitations:  It should be noted that using the metabolic 
profiling approach does not elucidate the mechanism that may be disrupted in the 
experimental model, but provides direction and insight into potential mechanisms 
that would require further in-depth studies.  The data collected in these studies 
resulted in a number of unexpected findings that we are currently following up on.  
We chose to employ the OVX model as a means to define metabolic function 
under conditions of reduced female sex steroids concentrations.  Although it is 
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likely that decreases in estrogens are contributing to a number of these effects, we 
cannot rule out the possibility that other ovarian hormones are playing a critical 
role in defining these phenotypes.  Since estrogens affect multiple tissues, it is 
difficult to assess which effects are a direct result of reduced estrogen levels and 
which are secondary effects due to changes in other non-skeletal muscle tissues.  
It is critical to develop experimental models to specifically isolate estrogen 
signaling in skeletal muscle to determine the primary role for estrogens in skeletal 
muscle metabolism. 
Overall, utilization of the metabolic profiling approach in the OVX model 
demonstrates that metabolic disturbances in the OVX animal do not recapitulate 
the same metabolic profile observed in other rodent models of obesity.  Two 
frequently observed results include an accumulation of LC (107) and increase in 
skeletal muscle BCAA levels in both human and animal models of obesity (80).  
However, the OVX mice do not exhibit this metabolic profile, suggesting that 
more studies are needed to critically examine the mechanistic role of female sex 
steroids in the regulation of peripheral metabolism.  In summary, our data suggest 
that reduced ovarian function results in an increase in IMCL content that is not 
entirely explained by a reduction in the capacity of the mitochondria to utilize 
fatty acids.  Due to the critical relationship between insulin signaling and IMCL 
content, it will be important to examine alternative explanations for the 
accumulation of lipid in the skeletal muscle of the OVX animals.   
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Perspectives and Significance: The results from this study provide a 
critical base of knowledge in an understudied area of women’s health and we 
hope the data will provide critical direction for additional mechanistic studies to 
be conducted.  The OVX model is the most frequently used murine model to 
study menopause in women, however is likely most representative of women 
undergoing surgical-induced menopause prior to the onset of age-induced 
menopause.  Thus, the resulting data are also likely most relevant to women 
experiencing pre-mature ovarian failure or being treated for estrogen positive 
cancers.  Previous publications have shown that the surgical removal of ovaries or 
the onset of ovarian failure in women leads to adiposity, particularly in the 
visceral region, which corresponds with glucose intolerance and insulin resistance 
(32).  In addition, there are indications of altered responses to muscle loading and 
reduced force output by the muscle (52, 72).  We and others have observed many 
of the same effects in the OVX model, indicating the importance of the OVX 
model for issues relevant to women’s health (98, 147, 167, 182).  The novel 
aspect of our study is that we now demonstrate a more comprehensive metabolic 
phenotype of skeletal muscle in the OVX model, which will help to elucidate the 
underlying mechanisms responsible for changes induced under conditions of 
estrogen signaling disruption.  In conclusion, the data demonstrate the importance 
of considering each model of obesity independently and highlight the need for 
more research in order to understand the role of female sex steroids in the 
regulation of metabolic function. Specific metabolic profiles likely exist across 
multiple models of metabolic disease and each model should be evaluated 
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individually when assessing the mechanisms behind the development of 
metabolic dysfunction. 
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 Age BM (g) SEM VF (g) SEM IF (g) SEM Uterus 
(g) 
SEM 
SHAM 4 mos 23.46 0.526 0.262 0.03 0.175 0.009 0.070 0.009 
OVX 4 mos 28.37* 0.998 1.296* 0.18 0.575* 0.134 0.019* 0.005 
BM = body mass; VF = visceral fat; IF = inguinal fat; * Indicates statistically 
different from SHAM P%0.05 




SEM Feed Efficiency 
Body mass (g)/Food 
Intake (Kcal*day) 
SEM 
SHAM 4.943 0.096 1.139 0.007 
OVX 4.228* 0.33 1.457* 0.008 
 
  




Figure 3.1 (A-B): IMCLs quantified using direct fluorescent visualization were 
significantly elevated in ovariectomized (OVX) female mice in both the (A) 
plantaris and (B) soleus muscle groups compared to age matched sham surgery 
(SHAM) female mice. N=3 animals/group and 50 fibers/muscle quantified.  * 





Figure 3.2 (A-B): Representative images of IMCL through BODIPY (493/503) 
staining of neutral lipid droplets and nuclei (DAPI-blue) within (A) skeletal 
muscle cross-sections of soleus and plantaris muscle and (B) single muscle fibers 
from SHAM and OVX age matched female mice. 
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Figure 3.3 (A-B): OVX female mice demonstrated significant elevations in (A) 
CD36/FAT protein and (B) FABPpm in the plantaris muscle compared to age 
matched SHAM animals. Example western blots are presented for each target. 





Figure 3.4 (A-D): OVX animals exhibited significant reductions in various 
acylcarnitine species coupled with lower carnitine levels in the whole 
gastrocnemius muscle compared to age-matched SHAM animals. (A) OVX 
female mice demonstrated a trend (p=0.06) for lower levels of long chain (LC; 
C16-C18) acylcarnitine species compared to age matched SHAM animals. (B) No 
differences between OVX and age-matched SHAM mice were detected for 
medium chain (MC, C10-12) acylcarnitine species. (C) OVX female mice had 
significantly lower levels of short chain (SC; C2-C5) acylcarnitine species 
compared to age matched SHAM animals. (D) OVX female mice had 
significantly lower levels of free carnitine compared to age matched SHAM 





Figure 3.5: No differences in the whole gastrocnemius skeletal muscle malonyl 
CoA content was detected between SHAM and OVX age matched female mice. 









Figure 3.6 (A-E): OVX mice exhibit no changes in whole gastrocnemius muscle 
pyruvate or lactate levels, but exhibit selective differences in Krebs cycle 
intermediates compared to age-matched SHAM mice. (A) OVX mice exhibited 
no differences in skeletal muscle lactate and pyruvate levels compared to age 
matched SHAM animals.  (B) OVX animals had significantly higher levels of 
citrate levels compared to age matched SHAM animals. (C) No significant 
differences in alpha ketogluterate were detected in the gastrocnemius muscle 
between age matched OVX and SHAM female mice.  (D) OVX mice 
demonstrated significant elevations in skeletal muscle succinate levels compared 
to age matched SHAM female mice.  (E) No significant differences were detected 
in skeletal muscle fumarate or malate levels between OVX and SHAM groups. 




Figure 3.7 (A-D): OVX animals exhibited significantly lower levels of various 
amino acid species in the gastrocnemius muscle compared to age matched SHAM 
animals.  (A) OVX mice had significantly lower levels of alanine, and no 
difference in glycine levels compared to SHAM animals.  (B) OVX mice had 
significantly lower levels of serine, leucine/isoleucine, glutamate in skeletal 
muscle compared to SHAM animals.  (C) OVX mice had significantly lower 
levels of proline and histidine, and no differences in valine, aspartate, or arginine 
levels compared to SHAM animals.  (D) No differences were detected methionine, 
phenylalanine, tyrosine, ornithine, or citrulline in the skeletal muscle between the 
OVX and SHAM groups.  Amino acid abbreviations are as follows:  alanine (Ala), 
serine (Ser), leucine/isoleucine (Leu/Ile), glutamate (Glx), proline (Pro), histidine 
(His), glycine (Gly), valine (Val), aspartate (Asx), arginine (Arg), methionine 
(Met), phenylalanine (Phe), tyrosine (Tyr), ornithine (Orn), and Citrulline (Cit). 




Figure 3.8: Significant decreases in odd chain acylcarnitine species 
propionylcarnitine (C3) and unsaturated isovalerylcarnitine (C5:1) in the whole 
gastrocnemius muscle from the OVX compared to age matched SHAM mice.  No 
significant differences were detected in isovalerylcarnitine (C5) acylcarnitine 
species or in the hydroxylated species ratio C5-OH/C3-OH.  N=6 animals/group.  




Figure 3.9 (A-E):  
Basal and stimulated oxygen consumption rates (OCR) of cultured single skeletal 
muscle fibers (isolated from the flexor digitorum brevis) from OVX and age 
matched SHAM mice.  (A) Basal OCR was significantly lower in OVX compared 
to SHAM animals. * indicates significant difference from SHAM (P%0.05). (B, 
C)  Maximal OCR rates induced by FCCP (calculated as percent change in OCR 
from baseline) in the presence of either palmitate (PA, 50µM) or pyruvate (Pyr, 
10mM) were significantly reduced in skeletal muscle fibers from OVX compared 
to SHAM animals.  However, no differences were detected in OCR responses to 
PA stimulation or Pyr stimulation alone. # indicates significantly different from 
SHAM basal (P%0.05), $ indicates significantly different from OVX basal 
(P%0.05), + indicates significantly different from SHAM FCCP (P%0.05).  (D, E) 
In response to PA or Pyr stimulation spare respiratory capacity (absolute 
OCRFCCP/absolute OCRbasal) was significantly reduced in OVX single muscle 
fibers compared to age matched SHAM single muscle fibers. N=5 animals/group.  




Figure 3.10 (A-B): Mitochondrial enzyme content did not differ in the whole 
gastrocnemius muscle between SHAM and OVX mice. (A) Mitochondrial 
enzymes responsible for the initial steps of #-oxidation of fatty acids VLCAD, 
LCAD, and MCAD did not differ between SHAM and OVX animals. (B) 
Mitochondrial respiratory chain complexes I-V did not differ between SHAM and 
OVX animals. N=5 animals/group.   
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Chapter 4: BRCA1 is a Novel Regulator of Lipid Metabolism in Skeletal 
Muscle 
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ABSTRACT: (250 word max) 
Breast cancer type 1 susceptibility protein (BRCA1) was recently 
identified as a regulator of lipid metabolism in breast tissue through an interaction 
with the phosphorylated form of Acetyl CoA Carboxylase (ACC-p).  In skeletal 
muscle, ACC influences lipid dynamics through enzymatic production of malonyl 
CoA (MaCoA), a known regulator of mitochondrial fatty acid transport and fatty 
acid synthesis.  The purpose of this investigation was to define a functional role 
for BRCA1 in skeletal muscle using a translational approach.  In both mice and 
humans, we identified the presence of multiple isoforms of BRCA1 in skeletal 
muscle.  In response to an acute bout of exercise, we found increases in the 
interaction between the native forms of BRCA1 and ACC-p.  Decreasing BRCA1 
expression using an shRNA approach in cultured primary human myotubes 
resulted in increased storage of intracellular lipid, and reduced insulin-induced 
Akt signaling which corresponded to impaired mitochondrial function.  
Collectively, these data reveal BRCA1 as a regulator of metabolic function in 
skeletal muscle and provides a novel target to consider in our understanding of 




Breast cancer 1 early onset (BRCA1) is recognized as an estrogen sensitive 
human tumor suppressor gene (142, 211).   Genetic variation in the BRCA1 gene 
is associated with increased risk for the development of breast cancer and/or 
tumorigenesis in reproductive tissues (60). The BRCA1 gene produces either a full 
length breast cancer type 1 susceptibility protein (BRCA1) or through 
alternatively splicing two documented variants, BRCA1$11 or BRCA1$11b, 
both of which lack a nuclear localization signal (212).  Recently, BRCA1 was 
identified as a regulator of lipid metabolism in human breast cancer cells (MCF7) 
as a result of direct interaction with the phosphorylated form of acetyl CoA 
carboxylase (ACC-p) at the BRCA1 C-terminal BRCT domains (54).  The 
interaction encourages the maintenance of the phosphorylated state of ACC 
thereby altering lipid metabolism in the MCF7 cell line (126, 148).  
 ACC has two isoforms, ACC1 or ACC2, with ACC2 containing an extra 
146 amino acids in the NH2-terminus region (2, 193).  ACC activity is negatively 
regulated by phosphorylation of residue Ser79 on ACC1 and Ser221 on ACC2.  In 
the active form (i.e. dephosphorylated), ACC catalyzes the carboxylation of acetyl 
CoA into malonyl CoA (MaCoA).  Changes in cellular MaCoA content can alter 
intracellular lipid dynamics in two specific manners (140, 160, 213).  MaCoA 
directly contributes to de novo synthesis of palmitic acid via fatty acid synthase 
(FAS) and MaCoA also allosterically inhibits carnitine palmitoyltransferase-I 
(CPT-1) a mitochondrial long chain fatty acid transporter (140).  Thus, in 
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mammary tissue the ability of BRCA1 to affect ACC activity alters cellular lipid 
concentrations by indirectly regulating rates of fatty acid synthesis and/or the flux 
of fatty acids into the mitochondria.   
In response to increased energetic demand, such as during exercise, 
skeletal muscle increases fatty acid entry into the mitochondria through CPT-1 
mediated transport (85).  During acute exercise, this rate is enhanced in muscle by 
a reduction in MaCoA content due to reduced ACC activity (160) with the 
inhibition of ACC mediated by AMP activated protein kinase (AMPK) (213).  
Since regular exercise is known to encourage metabolic health, multiple 
investigations have targeted this metabolic mechanism in an effort to treat 
metabolic disease.  ACC function is critical to the regulation of lipid metabolism 
in skeletal muscle since genetic ablation of ACC resulted in higher basal and 
insulin stimulated palmitate oxidation rates (3).  Collectively, these results 
indicate that ACC plays an important role in skeletal muscle metabolism however 
key regulators of ACC remain unidentified.    
A previous investigation has shown BRCA1 mRNA is expressed in 
C2C12 myoblasts, which would suggest a possible role in skeletal muscle (109).  
However, to our knowledge no studies have mechanistically examined the role of 
BRCA1 in skeletal muscle.  Thus, the purpose of this investigation was to 
establish if BRCA1 was expressed in skeletal muscle and determine whether it 
serves as a regulator of metabolic function.  Using an integrative and translational 
approach, we have identified that BRCA1 is expressed in both mouse and human 
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skeletal muscle and plays a critical metabolic function in the skeletal muscle cell.  
These results indicate that BRCA1 function extends beyond reproductive tissues 
suggesting that broader roles across multiple tissues should be evaluated.  
MATERIALS AND METHODS: 
Animals: The University of Maryland Institutional Animal Care and Use 
Committee (IACUC) Review Board approved all aspects involving animal 
research.  Male and female C57Bl/6 mice ranging from 8-10 weeks were utilized 
in this study.  Two groups of C57Bl/6 mice were divided into an exercise (Male 
n=6; Female n=7) or sedentary (Male n=6; Female n=7) group.  All animals were 
treadmill acclimated and then only the exercise group was subjected to an acute 
bout of treadmill exercise (Male=21.92±0.57m/min; 40.1±2.75min; 5% incline) 
(Female=26.57±0.30 m/min; 36.5±4.3 min; 5% incline) while the sedentary 
animals were placed on the treadmill in a stationary position for an equivalent 
time.  The males were run at a lower speed to maintain similar relative intensities 
between the males and females. At the conclusion of exercise, animals were 
euthanized and skeletal muscle was harvested, snap frozen in liquid nitrogen, and 
stored at -80oC. 
Human Subjects: The Ethics Committee of the Karolinska Institutet approved all 
aspects of this study. Twenty-four healthy subjects were included in the study, 13 
males and 11 females, all of who gave their informed consent to participate.  The 
mean (range) age, height, and weight were 26 (21–30) yrs, 177 (158–190) cm, 
and 75 (58–90) kg, respectively.  The mean (range) maximal oxygen consumption 
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(VO2max) was 48 (43–64) ml)kg-1)min-1.  Well-trained subjects (VO2max > 65 
ml)kg-1)min-1) were excluded to maximize the subjects’ exercise responses (173).  
Skeletal muscle biopsies from m. vastus lateralis (VL) were obtained using the 
percutaneous needle biopsy technique at rest (prior to the exercise bout) and at 30 
min after the exercise bout, alternating between the legs.  All biopsy samples were 
frozen in liquid nitrogen and stored at -80° C until further analysis.  
Mouse mRNA Analysis: Isolation of RNA and subsequent cDNA synthesis from 
the gastrocnemius muscles and mouse testes (positive control) was performed 
according to the previously described techniques (98, 188).  Specific primers for 
mouse Brca1 were as follows: forward 5’-CAC AGC GTA TGC CAG AGA AA-
3’ and reverse 5’ATC CTG GGA GTT TGC ATT TG-3’.   
Human mRNA Analysis: Total RNA from the skeletal muscle biopsies was 
isolated using standard methods (34) and real-time RT-PCR was used to measure 
two short BRCA1 splice variants (BRCA1 !11, BRCA1 !11b) and total BRCA1 
(BRCA1 total).  Amplicons were synthesized using previously described 
sequences (212).  GAPDH was used as an internal control (4352934E, Applied 
Biosystems Inc.).  Primer efficiency was tested with standard titration curves and 
did not differ between the primer pairs.  The expression of each target was 
determined by 2-DDCT (DeltaDelta Ct method) (214).   
Homogenization.  Mouse skeletal muscle was mechanically homogenized 
according to previously described techniques (98, 216).  Human skeletal muscle 
biopsies were homogenized on ice using glass-on-glass homogenizers in RIPA 
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buffer (150 mM NaCl, 10 mM Tris-HCl, 5 mM EDTA, 0.5 % Na Deoxycholate, 
0.1 % SDS, 1 % Triton X-100, Protein inhibitor cocktail complete mini (Roche 
Diagnostics)).  Total protein was determined in each sample using the Pierce 
BCA protein assay (mouse) or Bradford protein assay (human) as previously 
described (97, 153).   
BRCA1 Immunoprecipitation.  Immunoprecipitation of endogenous BRCA1 
protein in mouse (500µg total protein) or human (150µg total protein) skeletal 
muscle homogenate was performed with 2µg BRCA1 antibody (I-20, sc-646, 
Santa Cruz Biotechnology, Santa Cruz, CA) and incubated, rocking, overnight at 
4 oC.  The antigen-antibody complex was combined with protein A affinity and 
then washed through repeated centrifugation steps.  After the final wash the pellet 
was suspended in sample buffer and heated to 100 oC for 5 min.  The sample was 
then cooled and the eluted protein was loaded onto an SDS-PAGE gel for western 
blot analysis.   
Immunoblotting analysis.  Immunoblotting for either BRCA1 
immunoprecipitation solution or whole muscle homogenate protein was 
performed as previously described (97, 98, 219).  Membranes were probed with 
an antibody specific for BRCA1 (I-20; or D-20)(1:200; Santa Cruz Biotechnology, 
Santa Cruz, CA), ACC-p or ACC total (1:1000; Cell Signal; Boston, MA), Akt-p 
or Akt total (1:1000; Cell Signal; Boston, MA), &-actinin (1:5000; Sigma-Aldrich; 
Saint Louis, MO), RFP (1:2000; Thermo Scientific, Waltham, MA).  MCF7 cell 
lysates or mammary gland tissue from BRCA1 knockout mice (BRCA1 MG KO) 
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were used as a positive or negative control, respectively.  BRCA1 MG KO lysates 
also served as a positive control to detect the BRCA1 protein short splice variants 
(BRCA1!11, BRCA1!11b) as previously described (10, 41, 145, 202).   
Nuclear and Cytoplasmic fractions and BRCA1 Immunoblotting. Nuclear and 
cytoplasmic fractions were prepared using a Nuclear and Cytoplasmic Extraction 
Kit (NE-PER® Nuclear and Cytoplasmic Extraction Reagents, Thermo Scientific 
78833) as previously described (120). Purity and enrichment of nuclear fractions 
was demonstrated by measuring nuclear protein Lamin A/C and the cytosolic 
protein #-tubulin (T5201; Sigma-Aldrich; Saint Louis, MO) as previously 
described (75). 
Mouse Malonyl CoA Measures. Malonyl CoA measures were performed on the 
gastrocnemius muscles from sedentary and acute exercise female and male mice 
as previously described (97). 
Human Myoblast Cell Culture. Human skeletal muscle myoblasts and medias 
were purchased from Zen-bio (RTP, Research Triangle Park, N.C).  Human 
skeletal myoblasts were derived from the vastus lateralis muscle biopsy from a 
healthy, lean (normal BMI), twenty four year old female and only used at low 
passage number (<7).  Myoblasts were induced to differentiate to myotubes upon 
reaching ~90% confluency.  All plates were visually examined to ensure 
myotubes covered ~90% of the well prior to any experimental utilization. 
Adenovirus shRNA-hBRCA1 Myotube Infection. To reduce BRCA1 content in 
the human myotubes, the cells were transduced with either scrambled shRNA 
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adenovirus (scrambled-shRNA) or adenovirus containing an shRNA sequence 
targeting the coding region of BRCA1 (nt.530-550_NM_007294)(shRNA-
hBRCA1) and containing a red fluorescent protein tag overnight (Vector Biolabs, 
Philadelphia, PA).  Myotubes were then returned to regular growth media for 
48hrs and equivalent adenovirus infection was confirmed via imaging detection of 
RFP.  BRCA1 mRNA was isolated from adenovirus infected human myotubes as 
previously described (123).  Reduction in BRCA1 mRNA expression was 
confirmed in human myotubes 72hrs post adenovirus infection using the same 
primers as above for BRCA1 total, BRCA1 !11, BRCA1 !11b.   
Mitochondrial oxygen consumption. Mitochondrial oxygen consumption rates 
were measured in shRNA-hBRCA1 or scrambled-shRNA treated human 
myotubes similar to our previously described technique (97, 175).  In parallel 
plates, ACC phosphorylation was assessed after AICAR treatment in the same 
myotubes with either normal or reduced BRCA1 content. 
Human Myotube Insulin Signaling. Scrambled-shRNA or shRNA-hBRCA1 
treated human myotubes were serum starved for 4hrs in DMEM.  Myotubes were 
then either control treated or treated with 50nM insulin for 30 minutes as 
previously described (187).  Protein was then isolated from control treated or 
insulin treated scrambled-shRNA or shRNA-hBRCA1 human myotubes as 
previously described (190).  
Human Myotube Palmitate/Oleate Incubation and Bodipy Imaging. shRNA-
hBRCA1 or scrambled-shRNA treated human myotubes were incubated in 30µM 
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BSA-conjugated palmitate/oleate mixture in DMEM for 4hrs as previously 
described (207).  Myotubes were then stained with BODIPY (Molecular Probes, 
Carlsbad Calif, USA) as previously described (189). Myotubes were imaged with 
a Zeiss Axiovision 4 (Zeiss, Oberkochen, Germany) as previously described (106, 
207).  
Human Myotube ROS measures and imaging. Scrambled-shRNA or shRNA-
hBRCA1 treated human myotubes were placed in H2-DCF supplemented KRB 
buffer for 30 mins at 37° and then washed 3 times.  H2-DCF signed was 
quantified using a fluorescent plate reader (H2, Biotek, Burlington, VT) as 
previously described.  The myotubes were also imaged Zeiss Axiovision 4 (Zeiss, 
Oberkochen, Germany). 
Statistical Analysis 
All data are represented as the mean ± SEM.  Statistical analysis was 
conducted using ANOVA or t-test approaches with post-hoc tests (Tukey) 
employed when appropriate.  A P-value of %0.05 was considered significant.    
RESULTS: 
Brca1 Expression in Mouse Skeletal Muscle. In mouse skeletal muscle, Brca1 
mRNA and protein were detectable (Figure 4.1A-B).  In addition, using standard 
immunoblotting or an immunoprecipitation approach with different antibodies 
specific to either the N- or C-terminus region we consistently detected Brca1 (220 
kDa) in whole muscle homogenates (Figure 4.1 B-C).  The resulting protein mass 
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is consistent with previously published data concerning BRCA1 in other tissues 
(126, 146, 207, 211).   
In reproductive tissue, BRCA1 is an estrogen sensitive gene (154), 
however in the gastrocnemius muscle of mice we detected greater levels of both 
the full-length and short (Brca1$11, 85kDa as previously defined (10)) Brca1 
splice variants in males compared to females (Figure 4.1D).  Full-length Brca1 
protein levels did not differ between gastrocnemius and tibialis anterior (TA) 
muscles within female or male mice, respectively (Figure 4.1E,F).  Further, Brca1 
protein was undetectable in the soleus muscle (Figure 4.1E,F).  In female mice, no 
differences were detected in Brca1$11 protein content in the soleus, TA, or 
gastrocnemius muscle (Figure 4.1E).  In contrast, Brca1$11 was significantly 
higher in TA and soleus compared to the gastrocnemius muscle in male mice 
(P"0.05) (Figure 4.1F).  
Mouse Brca1 Acc-p Acute Exercise Induced Protein Interaction. In order to 
assess the potential interaction between the endogenous forms of Acc-p and Brca1, 
mice were subjected to an acute bout of treadmill exercise.  Exercise induced 
significant elevations in the ratio of Acc-p/Acc-total in both male and female 
gastrocnemius muscle compared to sedentary animals (P"0.05) (Figure 4.2A,B).  
As expected, MaCoA content significantly decreased in response to the exercise 
bout in the female animals, but surprisingly the increase in Acc-p levels did not 
correspond to a decline in MaCoA levels in the male mice (Figure 4.2C).  Further, 
MaCoA levels in sedentary female skeletal muscle were significantly higher 
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compared to sedentary males (P%0.05) (Figure 4.2C).  In response to the exercise 
bout there was a significant increase in Brca1-Acc-p protein-protein interaction in 
both female and male gastrocnemius muscle compared to sedentary animals 
(P"0.05) (Figure 4.2D).  However, in females, the exercise induced Brca1-Acc-p 
interaction tended to be greater than males (P=0.09) (Figure 4.2D).  
BRCA1 mRNA and Protein Expression in Human Skeletal Muscle.  In an 
effort to translate the observations found in a murine model, similar experiments 
were performed in humans.  BRCA1 mRNA (full length and splice variants) was 
detected in human skeletal muscle, with no differences between sedentary women 
and men (Figure 4.3A).  The two well-recognized short variants in human tissue, 
BRCA1!11 and BRCA1!11b mRNA, were readily expressed in human skeletal 
muscle with no sex differences (Figure 4.3B,C).  Using antibodies specific to the 
C-and N-terminal regions, the presence of BRCA1 protein in human skeletal 
muscle was verified (Figure 4.3D), with no detectable sex differences (Figure 
4.3E).  Previous research has suggested that BRCA1 isoforms exhibit specific 
intracellular localization (146, 212).  Thus, BRCA1 protein content was measured 
in nuclear and cytosolic fractions from male and female skeletal muscle biopsies.  
The short splice variants (lacking nuclear localization signal, BRCA1$11 and 
BRCA1$11b) of BRCA1 were almost exclusively detected in the cytosolic 
fraction whereas the full length BRCA1 protein was predominantly detected in 
the nuclear fraction (Figure 4.3F).  Although mRNA for BRCA1!11 and 
BRCA1!11b were individually detected, it was not possible to distinguish the 
protein products due to similar molecular weights. 
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Acute Exercise in Humans Induced ACC-p and BRCA1 Protein Interaction. 
To assess the role of BRCA1 in skeletal muscle, women and men performed an 
acute bout of exercise.  The exercise bout resulted in a significant increase in 
ACC-p/ACC compared to pre exercise values (P"0.05) (Figure 4.4A-B).  There 
was considerable individual variability in the magnitude of interaction between 
ACC-p and BRCA1 in both male and females prior to and after the completion of 
the exercise bout (Figure 4.4C).  When comparing the average group response, 
males demonstrated a significant increase in endogenous ACC-p and BRCA1 
interaction (P"0.05), while women presented with a trend for increased 
endogenous protein interaction in response to the acute exercise bout (P=0.07) 
(Figure 4.4C).   
Reductions in BRCA1 expression results in accumulation of intramyocellular 
lipid and reduced insulin signaling.  Infection of human myotubes with shRNA-
hBRCA1 resulted in nearly undetectable BRCA1 mRNA expression compared to 
infection with scrambled shRNA (Figure 4.5A).  Reduced BRCA1 expression 
(shRNA-hBRCA1) in human myotubes resulted in accumulation of intracellular 
neutral lipid storage compared to control myotubes (scrambled-shRNA) (Figure 
4.5B).  When myotubes were treated with conjugated-FFA, we observed an 
additional increase in lipid storage in myotubes with reduced BRCA1 expression 
compared to treated control myotubes (Figure 4.5B).  Myotubes with reduced 
BRCA1 expression exhibited reduced Akt phosphorylation in response to insulin 
treatment (50nM for 30mins) compared to the insulin response in the control 
myotubes  (Figure 4.5C).   
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Reductions in BRCA1 expression results in decreased mitochondrial oxygen 
consumption in human myotubes.  Human myotubes with reduced BRCA1 
expression exhibited lower basal oxygen consumption rates (OCR) compared to 
scrambled-shRNA myotubes (P"0.05) (Figure 4.5D).  OCR was lower in shRNA-
hBRCA1 treated myotubes after mitochondrial uncoupling induction compared to 
scrambled-shRNA myotubes (Figure 4.5E).  Similar reductions in OCR were seen 
between groups after the addition of palmitate (Figure 4.5F).  
Reductions in BRCA1 expression results in reduced AICAR-induced 
phosphorylation of ACC in human myotubes.  AICAR can induce-
phosphorylation of ACC via activation of AMPK, thus we determined the ability 
of AICAR to induce phosphorylation of ACC under reduced BRCA1 conditions.  
ACC-p content did not increase after AICAR treatment of the human myotubes 
infected with shRNA-hBRCA1 compared to scrambled-shRNA treated myotubes 
(Figure 4.5G-H). However, we were surprised to find that reducing BRCA1 
content resulted in elevated phosphorylation of AMPK and thus increased 
phosphorylation of ACC suggesting that BRCA1 is not required for 
phosphorylation of ACC. 
Reduced BRCA1 expression increases ROS production leading to AMPK 
phosphorylation.  In order to determine why ablation of BRCA1 in the human 
myotubes led to hyper-activation of AMPK, we assessed global ROS content in 
myotubes with or without BRCA1.  Using a global ROS indicator (H2-DCF) 
(Figure 4.6A-B) we found higher ROS content in myotubes transduced with 
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shRNA-hBRCA1 compared to scrambled-shRNA treated myotubes (Figure 4.6A-
B). 
DISCUSSION: 
BRCA1 is a large, polyfunctional protein (220kDa) that regulates a variety 
of intracellular functions through multiple mechanisms including protein-protein 
interactions (48).  To date, BRCA1 has been predominantly recognized as a cell 
cycle regulator and a DNA damage repair protein in reproductive tissues (48).  
However, the data presented here provide evidence for a novel functional role for 
BRCA1 as a regulator of metabolic function in skeletal muscle of both mice and 
humans (Figure 7).  Specifically, in response to an energetic stress (i.e. acute 
exercise) there is a significant increase in the interaction of BRCA1 with the 
phosphorylated form of ACC.  Reducing BRCA1 content in human myotubes 
resulted in increased lipid storage, decreased insulin signaling, reduced 
mitochondrial function, and enhanced ROS production.  Overall, our observations 
provide evidence for a previously un-described role for BRCA1 and lend support 
for more detailed examinations of the role of BRCA1 as a metabolic regulator in 
skeletal muscle. 
 Genetic alteration in the BRCA1 sequence and/or alterations in BRCA1 
expression are strongly correlated with risk of tumorigenesis in reproductive 
tissues (134).  However, a functional role involving BRCA1 in skeletal muscle 
has gone unrecognized even though BRCA1 mRNA content is known to increase 
in differentiating C2C12 myoblasts (109).  Our data significantly extend this 
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initial observation by demonstrating that both the long and short BRCA1 isoforms 
are present at the mRNA and protein level in adult mouse skeletal muscle and in 
human skeletal muscle.  Consistent with previous literature, the full-length 
BRCA1 proteins, which have an intact NLS (202, 212), were detected 
predominantly in the nuclear fraction of human skeletal muscle while the short 
splice variants, which lack an NLS (212), were detected in the cytosolic fraction.  
It is well established that BRCA1 is an estrogen-sensitive gene (35), thus it was 
surprising to find higher Brca1 and Brca1$11 content in male than in female 
mouse gastrocnemius muscle.  However, this sex difference did not translate to 
human skeletal muscle, as neither BRCA1 mRNA nor protein content differed 
across sexes.  Finally, few differences were detected across skeletal muscle 
groups in mouse Brca1 expression and protein content.  In fact, only the male 
mice presented with significant differences in BRCA1$11 across muscle groups 
with the TA and the soleus muscles having greater levels of BRCA1$11 
compared to the gastrocnemius muscle.  In male mice, including the soleus 
muscle, most muscles are composed of a mixed phenotype thus it is unclear why 
TA and/or soleus muscle would have significant differences in only BRCA1$11 
(24).  In conclusion, our data demonstrate that multiple recognized forms of 
BRCA1 are detectable at both the mRNA and protein level in skeletal muscle 
from both mice and humans. 
In a series of elegant experiments, BRCA1 was previously shown to 
directly bind to the phosphorylated form of ACC in mammary cells (126, 148).  
ACC is a critical regulator of lipid metabolism as it catalyzes the production of 
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MaCoA in skeletal muscle (3, 160, 213).  MaCoA can act as a potent allosteric 
inhibitor of CPT-1 or can serve as a precursor for lipid synthesis (137, 213), with 
the former being the likely mechanism for ACC regulation of lipid metabolism in 
skeletal muscle (160, 191).  Using an acute bout of exercise to energetically 
challenge the muscle resulted in increased ACC-p content in skeletal muscle.  The 
increase in ACC-p also resulted in increased interaction between BRCA1 and 
ACC-p.  Further, our data in the mouse indicate differential Brca1/Acc-p 
interactions in females and males both at rest and in response to an acute bout of 
exercise, which was also associated with differing content of MaCoA in the same 
muscle.  To the best of our knowledge, this is the first time a sex-based difference 
in skeletal muscle MaCoA content has been demonstrated.  Re-analysis of data 
from a previous publication (204) where male and female mice were treated with 
AICAR demonstrated a similar finding.  Specifically, female mice presented with 
higher levels of resting MaCoA and a greater response to AICAR treatment than 
age-matched male mice.  Unfortunately, due to limited sample amounts we were 
not able to directly measure MaCoA content in the human samples to compare the 
BRCA1-ACC-p interaction in a quantitative fashion, thus it is currently unclear if 
there was also a differential response in our human samples.  Regardless, the data 
clearly indicate that in response to an acute bout of exercise there is a resulting 
increase in the interaction of BRCA1-ACC-p in skeletal muscle in both mice and 
humans. 
To determine if BRCA1 plays a critical role in regulation of skeletal 
muscle metabolic function we reduced BRCA1 expression through shRNA 
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technology.  Reducing BRCA1 content in human myotubes resulted in increased 
neutral lipid storage and resulted in a concurrent reduction in mitochondrial 
function in the myotubes.  Thus, our results in skeletal muscle are in agreement 
with previous findings in MCF7 cells that reductions in BRCA1 expression results 
in increased lipid storage (148).  In muscles cells, ACC2 localizes to the 
mitochondria while in non-muscle cells, BRCA1 can localize to the mitochondria 
(2, 37) which when coupled with our results suggests a likely role for BRCA1 
regulating mitochondrial function.  Our data would indicate that BRCA1 is at 
least in part influencing mitochondrial function via interaction with ACC, 
however alternative mechanisms are likely contributing.  Specifically, our data 
indicate ACC phosphorylation can occur independent of BRCA1 since loss of 
BRCA1 induced an increase in AMPK phosphorylation by inducing ROS 
production.  Others have found in breast cancer cells, that BRCA1 reduced ROS 
production and protected macromolecules against oxidative damage (172).  The 
increased production of ROS in the absence of BRCA1 likely explains the hyper-
activation of AMPK and thus downstream phosphorylation of ACC.  Specifically, 
in cultured skeletal muscle cells ROS exposure induces substantial increases in 
AMPK phosphorylation (92).  These data suggest that phosphorylation of ACC is 
not dependent upon BRCA1 expression, but would suggest that BRCA1 
encourages the maintenance of ACC phosphorylation (148).   
Loss of BRCA1 expression also resulted in a lower Akt phosphorylation 
response to acute insulin exposure suggesting that optimal insulin signaling 
requires BRCA1.  This is in contrast to results in breast cancer cells where 
! *$!
BRCA1 is thought to negatively regulate the oncogenic function of Akt (226).  At 
this time, BRCA1 expression appears to be necessary for optimal metabolic 
function in skeletal muscle, however further examination of the role of BRCA1 is 
necessary.  In addition, since our data suggest that decreases in BRCA1 could 
contribute to metabolic disease susceptibility, further and more detailed 
exploration of interventions that alter BRCA1 content are warranted. 
Due to the large size of the BRCA1 gene there is a substantial amount of 
documented genetic variation, which results in altered protein function and/or 
expression (143).  Given our data, such variation may affect metabolic function 
and could be linked to a form of metabolic disease (i.e. obesity, type 2 diabetes, 
etc).  However, to our knowledge no single nucleotide polymorphisms have been 
identified in the BRCA1 gene in genome-wide association studies relating such 
polymorphisms to metabolic dysfunction.  The phosphorylated form of ACC 
interacts with BRCA1 in the C-terminal region, specifically in the BRCT domains 
(66).  Although the BRCT domains are conserved across all confirmed BRCA1 
isoforms (126) substantial genetic variation is often present in this region (115).  
Since the phosphorylated form of ACC binds to the BRCT domain within BRCA1, 
it is possible that specific sequence variation in this domain may contribute to 
variations in the degree of BRCA1 function in humans.  Indeed, in response to the 
acute bout of exercise our subjects had a substantial amount of variation in the 
magnitude of BRCA1-ACC-p interaction.  Further examination of this hypothesis 
will be necessary to determine if documented SNPs within the BRCT domains of 
BRCA1 are associated with risk development of metabolic disease in humans. 
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In summary, we have identified that BRCA1 expression is an important 
regulator of metabolism in both mouse and human skeletal muscle.  These 
findings significantly extend our understanding of BRCA1 physiology by 
considering mechanistic aspects outside of its classically known role as a 
regulator of DNA repair and cell cycle in reproductive tissues.  We propose that 
our data collectively identifies BRCA1 as a regulator of ACC dynamics and 
overall metabolic function of skeletal muscle.  Future studies will be necessary to 
examine the therapeutic potential of manipulating BRCA1 expression and/or 
function in skeletal muscle as a means to prevent the development of metabolic 
diseases. 
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Figure 4.1: Identification of Brca1 in male and female mouse skeletal muscle. (A)  
Brca1 mRNA detection identified in female mouse gastrocnemius muscle (SM) 
with mouse testes serving as a positive control (B) Protein identification and 
verification of Brca1 (220kDa) using an antibody comparison Ab1: (SC-I:20) 
Brca1 N-terminal specific antibody Ab:2 (SC-D:20) Brca1 C-terminal specific 
antibody.  (C) Immunoprecipitation Brca1 in female mouse skeletal muscle using 
Ab1 and Ab2. (D) Brca1 protein was greater in males compared to female mouse 
gastrocnemius muscle (P"0.05). No significant differences were detected between 
male and female mice for Brca1$11 (78kDa). Mammary gland from BRCA1 
knockout mouse (MG KO) served as a negative control for full length Brca1 and a 
positive control for the Brca1 splice variant (Brca1$11).  (E) No differences in 
Brca1 and Brca1$11 protein content in soleus, gastrocnemius, and tibialis anterior 
(TA) muscles from adult female mice were detected.  (F) In skeletal muscle from 
adult male mice, no differences across muscle groups were detected in Brca1 
protein content, while Brca1$11 content as significantly higher in the TA and 
soleus compared to the gastrocnemius muscle.  Total protein staining gels were 
used to ensure equal loading of protein across samples. Data are presented as 
mean + SEM (n=3 mice per group for western blotting measures) *P"0.05 female 




Figure 4.2: An acute bout of exercise increases endogenous Acc-p and Brca1  
interaction in skeletal muscle in adult male and female mice. (A-B) Acc-p levels  
were significantly higher in response to an acute bout of exercise in the  
gastrocnemius muscle from adult female and male mice compared to sedentary  
mice. (C) MaCoA levels were significantly higher in gastrocnemius muscles from  
sedentary female mice compared to sedentary male mice.  Adult female mice  
exposed to an acute bout of exercise had significantly lower MaCoA levels  
compared to the female sedentary mice and no significant differences were  
apparent in gastrocnemius muscle from male mice. (D) Interaction between Brca1  
and Acc-p was greater in gastrocnemius muscle from sedentary females compared  
to sedentary males.  Brca1 and Acc-p interaction was significantly higher  
after an acute bout of exercise in gastrocnemius muscles from both male and  
female mice when compared to their sedentary counterparts. Data are presented as  
mean + SEM (n=6-7 per group) *P"0.05 sedentary vs. exercise; #P"0.05 male  





Figure 4.3. BRCA1 expression is detectable in biopsies taken from human vastus 
lateralis (VL). (A-C) No significant differences were detected in mRNA 
expression of all recognized human BRCA1 variants in skeletal muscle biopsies 
taken from males and females. All data were normalized to GAPDH (D). The 
presence of BRCA1 protein in human skeletal muscle was verified using 
antibodies specific to the N-terminus (Ab:1) or C-terminus (Ab:2).  (E) No 
significant differences in BRCA1 protein were detected between men and women 
in biopsies from the VL.  (F) Full length BRCA1 was detected predominantly in 
the nuclear fraction isolated from the VL from men and women whereas the 
BRCA1$11/ $11b splice variant was detected in the cytoplasmic fraction.  Cell 
lysates isolated from the mammary gland of BRCA1 knockout animals as a 
positive control for the BRCA1$11/ $11b splice variants.  Laminin was used as a 
nuclear control protein and #-tubulin as the cytoplasmic control protein.  Data are 
presented as mean + SEM (n=13 per group for mRNA analysis; n=5-6 per group 





Figure 4.4. An acute bout of exercise in men and women resulted in a greater  
interaction between the phosphorylated form of ACC and BRCA1 in muscle 
biopsies taken from the VL. (A-B) Significant increases were found in ACC-p 
content compared to pre exercise in both male and female subjects.  (C) In 
response to an acute bout of exercise in men and women, the majority of subjects 
had increased BRCA1-ACC-p interaction compared to pre exercise. Each line 
represents an individual subject and is marked with the sex and magnitude of 
response. Data are presented as mean + SEM (n=5-6 per group for BRCA1 











Figure 4.5. Reduction in BRCA1 content enhances neutral lipid storage and 
decreases mitochondrial function in primary human myotubes. (A) Human 
myotubes transduced with shRNA for human BRCA1 (shRNA-hBRCA1) 
presented with reduced BRCA1 total, BRCA1$11 and BRCA1$11b compared to 
cells infected with scrambled-shRNA.  (B) Myotubes with reduced BRCA1 
expression exposed to either BSA or 30uM palmitate/oleate conjugated BSA 
exhibited increased neutral lipid accumulation in myotubes compared to 
myotubes infected with scrambled shRNA. (C).  Insulin-induced phosphorylation 
of Akt was reduced in myotubes with reduced BRCA1 expression compared to 
control myotubes.  Myotubes were treated with 50nM insulin for 30 mins. (D) 
Basal OCR was reduced in shRNA-hBRCA1human myotubes compared to 
Scrambled-shRNA myotubes. (E) Uncoupling the mitochondria with FCCP 
resulted in a reduced OCR in shRNA-hBRCA1 myotubes compared to 
Scrambled-shRNA. (F) Palmitate stimulated OCR was significantly reduced in 
shRNA-hBRCA1 myotubes compared to Scrambled-shRNA myotubes. (G) No 
difference in mitochondrial protein ATP 5A was detected in scrambled-shRNA 
and shRNA-hBRCA1 myotubes.  Equal loading was confirmed through Red 
Fluorescent Protein (RFP).  (H) ACC-p response was attenuated in oligomycin 
treated shRNA-hBRCA1 compared to scrambled-shRNA. Data are presented as 
mean + SEM (n=3-5 per group for all analyses); *P"0.05 scrambled-shRNA vs. 





Figure 4.6.  Reduction in BRCA1 content enhances ROS production in primary 
human myotubes. (A) Human myotubes transduced shRNA-BRCA1 exhibit 
visual increases in ROS signal (green-marked with arrows) compared to cells 
infected with scrambled-shRNA.  (B) Myotubes with reduced BRCA1 (shRNA-
BRCA1) expression exhibited increased basal ROS production in myotubes 
compared to myotubes infected with scrambled shRNA. Data are presented as 
mean + SEM (n=3-5 per group for all analyses); *P"0.05 scrambled-shRNA vs. 
shRNA-hBRCA1 myotubes.  
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Chapter 5:  Deletion of Brca1 in adult skeletal muscle results in altered 
skeletal muscle function and protection from high fat diet-induced metabolic 
insults 
The following is a manuscript in preparation based on my final dissertation 
work.   
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ABSTRACT: 
Breast cancer type 1 susceptibility protein (BRCA1) is a large polyfunctional 
protein commonly associated with breast cell carcinoma in humans due to its 
established role as a cell cycle regulator.  Recently, we identified BRCA1 as a 
critical regulator of lipid metabolism in skeletal muscle.   However, the role of 
BRCA1 in an in vivo, adult skeletal muscle model has yet to be determined.  Here 
we employed an inducible, skeletal muscle-specific, Brca1 knockout mouse 
model to further elucidate the role of Brca1 in skeletal muscle.  At 10 weeks of 
age male and female mice were injected with a tamoxifen solution inducing flox-
mediated recombination of the Brca1 gene (KO) or vehicle-based solution in age-
matched wildtype (WT) mice.  The mice were then placed on a control (CD) or 
high fat diet (HFD).  Loss of Brca1 in skeletal muscle attenuated HFD-induced 
gains in body weight, visceral fat mass, and/or liver mass when compared to 
WT+HFD.  Female KO mice demonstrated an onset of kyphosis that was 
surprisingly attenuated by the HFD with no other groups exhibiting this effect.  
Regardless of diet, KO mice exhibited lower maximal treadmill speed compared 
to the WT+CD group.  In addition, KO mice demonstrated protection from HFD-
induced glucose intolerance when compared to the WT-HFD group.  Similarly, 
Brca1 KO mice had lower IMCL content in response to HFD compared to WT 
mice despite lower skeletal muscle mitochondrial function measures.  Lastly, loss 
of functional Brca1 resulted in less contraction-induced phosphorylation of Ampk 
and Acc in both KO+CD and KO+HFD mice.  However, basal Acc-p levels were 
higher in the sedentary muscle from KO+CD mice compared to WT+CD mice.  
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Collectively, these data indicate that loss of functional Brca1 in skeletal muscle 
attenuates the metabolic consequences of HFD despite impaired mitochondrial 
function and alterations in Ampk/Acc phosphorylation.   
INTRODUCTION: 
Whole body metabolic function is largely influenced by changes in skeletal 
muscle lipid and/or carbohydrate metabolism.  In particular, it is well documented 
that disruptions in the ability to either oxidize or store lipid is associated with a 
number of different chronic health conditions. Thus, the identification of 
mechanisms that regulate lipid metabolism in skeletal muscle is critical to 
elucidating approaches for attenuating the onset of various metabolic-based 
diseases.   
Breast cancer 1 early onset gene (Brca1) is a caretaker gene that is highly 
susceptible to mutations and predominantly associated with breast cancer in 
women (48, 50, 142, 184).  The corresponding protein to Brca1, breast cancer 
type 1 susceptibility protein (Brca1), is a large, polyfunctional protein that 
regulates a variety of intracellular mechanisms (23, 48, 50, 60, 148, 172).  
Historically, Brca1 is associated with mechanisms that regulate DNA repair or the 
cell cycle (48, 109, 184).  However, recent evidence has also implicated BRCA1 
as critical regulator of metabolic function in breast cancer cells (23, 126, 148).  
In MCF7 cells, Brca1 regulates lipid metabolism dynamics through direct 
interactions with the phosphorylated form of acetyl CoA carboxylase (Acc) (126, 
148).  When active, Acc inhibits lipid entry into the mitochondria through 
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production of malonyl CoA, a potent allosteric inhibitor of the mitochondria lipid 
transport enzyme, carnitine palmitoyl transferase-I (CPT-1) (140, 160, 213).  In 
addition, malonyl CoA directly contributes to de novo intracellular synthesis of 
palmitic acid through the enzymatic reaction catalyzed by fatty acid synthase 
(FAS) (140).  The interaction between Brca1 and Acc-p could maintain 
phosphorylation of Acc, thereby inactivating the enzyme and subsequently 
promoting CPT-1 activity (160, 161).  In addition, Brca1 has been found to 
localize to the mitochondria, suggesting a potential role in the regulation of 
mitochondrial function (37, 131).  Therefore, although Brca1 plays a critical role 
in regulation of metabolism in breast cancer cells, the role of Brca1 in other 
metabolically active tissues remains poorly defined.  
Although Brca1 is expressed in skeletal muscle, very little is known about the 
function of this protein in skeletal muscle.  Original descriptions of Brca1 in 
skeletal muscle were limited results that described increases levels of expression 
during the differentiation process of immortalized skeletal muscle myoblasts 
(109).  We have previously demonstrated in both murine and human, male and 
female skeletal muscle models that BRCA1 is present and, similar to human 
breast cancer cells, binds directly to the phosphorylated form of ACC (96).  
Further, we also demonstrated that loss of BRCA1 in human myotubes results in 
impaired mitochondrial function, leading to intramyocellular lipid accumulation 
(IMCL), impaired insulin stimulation, and increased reactive oxygen species 
(ROS) production (96).  Also, Brca1 expression appears to be critical to the 
regulation of metabolic function in cardiac muscle (178). Although the in vitro 
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evidence is compelling, it is unclear how critical Brca1 function is to skeletal 
muscle in vivo. 
  Therefore, the purpose of this study was to assess the in vivo functional role 
of Brca1 using a novel inducible skeletal muscle-specific knockout mouse.  Here 
we demonstrate that in vivo ablation of Brca1in skeletal muscle results in 
physiological alterations, including metabolic changes that implicate Brca1 as a 
critical regulator of skeletal muscle function.  
MATERIALS AND METHODS: 
Generation of HSA-Cre(+) Brca1 Flox (+/+) Mouse: Animals from a C57/BL6 
background with flanked flox sites surrounding exon 11 of the Brca1 gene 
(referred to as Brca1 Flox +/+) were bred with a skeletal muscle tissue-specific 
inducible CreER male mouse model (C57/BL6; HSA-Cre(+)) to generate HSA-
Cre (+) Brca1 Flox (+/+) animals, which were used for this study (47, 135) 
(Figure 1A,B,C).  
Animal Genotyping: All animals were genotyped for the presence of HSA-Cre 
and homozygote Brca1 Flox expression using genomic DNA. Primer sets F-5’-
GGCATGGTGGAGATCTTTGA-3’ and R-5‘-
CGACCGGCAAACGGACAGAAGC-3’ were used to screen for HSA-Cre (+) 
animals as previously described (135).  Amplification was performed with an 
initial denaturing step of 95oC for 5min; followed by 32 cycles of the following 
program: 94oC 30sec, 60oC 1min, 72oC 1min; the final cycle ended with 72oC for 
10min. Concurrently, all animals were also genotyped for Brca1 flox using primer 
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sets 5’-CTGGGTAGTTTGTAAGCATGC-3’ and 5’-
CAATAAACTGCTGGTCTCAGG-3’ where the Brca1 Flox amplicon is ~500bp 
and the wild type is ~450bp.  Amplification was performed with an initial 
denaturing step of 94oC for 3min; followed by 35 cycles of the following 
program: 94oC 1min, 60oC 2min, 72oC 1min; the final cycle ended with 72oC for 
3min. 
Brca1 recombination DNA/mRNA analysis: 
Cre-mediated recombination was confirmed through PCR analysis of 
genomic DNA isolated from the plantaris muscle using a DNA isolation kit 
(Qiagen, Valencia, Ca.).  Specifically primer Brca1 Flox-A-
5’CTGGGTAGTTTGTAAGCATGC-3’ and primer Brca1 Flox-E-
CTGCGAGCAGTCTTCAGAAAG-3’ were used to generate an amplicon that is 
approximately 621bp in length indicating the removal of the flox region of Brca1 
as previously described (47). Amplification was performed with an initial 
denaturing step of 95oC for 5min; followed by 30 cycles of the following 
program: 95oC 30sec, 54oC 1min, 72oC 30sec; the final cycle ended with 72oC for 
5min. 
To determine tissue specificity, total RNA was isolated from the heart, 
lung, liver, kidney, soleus, tibialis anterior (TA) and gastrocnemius muscle as 
previously described and RT/PCR was performed using Reverse Transcription 
and HotStarTaq PCR kits (Qiagen, Valencia, Ca.) (98).  PCR was performed 
using primer set B004-5’-CTGGGTAGTTTGTAAGCATGC-3’ and B006-5’-
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CTGCGAGCAGTCTTCAGAAAG-3’ which if recombination had occurred in 
the flox region of Brca1 an mRNA amplicon of ~600bp would be produced (98).  
Amplification was performed with an initial denaturing step of 94oC for 3min; 
followed by 35 cycles of the following program: 94oC 1min, 60oC 2min, 72oC 
1min; the final cycle ended with 72oC for 3min. 
Experimental Approach: 
Ten-week-old HSA-Cre (+) Brca1 Flox (+/+) male and female mice were injected 
with 12.75mg/mL tamoxifen (KO) or control (WT) solution for 5 consecutive 
days.  Upon completing injections mice underwent a 14-day washout period and 
then were assigned to either a control diet (CD; 10%kcal fat; D12450K) (KO + 
CD; WT+ CD) or high fat diet (HFD; 45% kcal fat; D12451) (WT+HFD; 
KO+HFD) (Research Diets Inc. New Brunswick, N.J.) for a duration of 10 weeks.  
Food intake and body weight were recorded for the duration of 10 weeks of 
feeding.  At the conclusion of 10 weeks mice were subjected to either a muscle 
fatigue protocol (n=6/group; paired males and females) as previously described 
(219) or underwent glucose tolerance testing, insulin tolerance testing, endurance 
treadmill testing, and isolated skeletal muscle mitochondrial measures (n=6-
10/group).  Upon completing these measures mice were humanely euthanized and 
tissue was flash frozen and stored at -80oC.  
Exercise Tolerance:  
 
 An endurance exercise test was administered for each of the four groups of 
mice.  The endurance test consisted of a three-day treadmill acclimation period 
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where animals were placed on the treadmill with the electrical shock grid in the 
rear turned on for 3 minutes and then the treadmill speed was increased to 
11m/min for 5 minutes each day as previously described (177).  Mice rested for 1 
day prior to the exercise test.  On the day of the test mice began running at 
11m/min and 5% incline and speed was increased 2m/min every 5 min to 
maximal speed.  Maximal speed was determined by each animal’s ability to 
remain on the treadmill for a minimum of 20sec bouts.  Failure was determined 
when animals remained on the shock grid for more than 15 continuous seconds.  
Exercise distance and exercise duration were recorded for each animal to assess 
exercise tolerance in each group of animals.   
 
In Situ Muscle Fatigue:   
 In situ muscle fatigue was measured on the right gastrocnemius muscle 
group from KO and WT, CD or HFD treated animals.  The contralateral limb 
served as a sedentary control limb as previously described (219).  Specifically, 
animals were anesthetized with isoflurane.  While the animal was lying prone the 
hindlimb was stabilized and the achilles tendon was released.  The proximal 
portion of the tendon was secured in a custom clamp and attached to a load cell 
(Grass Instruments FT03).  Contractions of the gastrocnemius group were induced 
by direct stimulation and single twitches were applied at different muscle lengths 
to determine the optimal length (resting length Lo).  With muscles set at Lo 
maximal tetanic force (Po) was measured and fatigue was induced through 90 Hz 
stimulation for 200 ms duration every 2 sec for 5 mins.  Skeletal muscle fatigue 
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was defined as an 80% loss of initial force.  Maximal tetanic tension was 
measured after fatigue development and expressed as a percentage of Po, to 
provide an index of fatigue.  The fatigued and contralateral gastrocnemius 
muscles were immediately removed, weighed, and frozen in liquid nitrogen.   
Immunoprecipitations and Immunoblotting Analysis:  
All protein content analysis was performed using the gastrocnemius 
muscle from either control or in situ fatigued limbs in both WT and KO animals 
consuming CD or HFD.  For detailed methods regarding Brca1 
immunoprecipiation from skeletal muscle homogenate, Acc-p, and all western 
blotting conditions please refer to Study 2 located in Chapter 4.  
Glucose/Insulin Tolerance Testing:  
Animals were fasted overnight in cages containing hardwood bedding 
prior to GTT, while animals retained access to their food for insulin tolerance 
tests (ITT).  Before injecting glucose/insulin on the day of the test, fasted (GTT) 
and non-fasted (ITT) basal blood glucose levels were measured.  Animals were 
then IP-injected with 0.001g glucose per gram body weight or, for insulin 
tolerance testing, 1.0 units of insulin per 1kg body weight of insulin solution 
dissolved 1:1000 in sterile 1xPBS.  Blood glucose levels were measured with a 
glucometer (AlphaTrak from Abbott) at pre-injection (0) and 30, 60, 90 and 120 
minutes post glucose or insulin injection.  A 72-hour washout period occurred 
between GTT and ITT procedures.   
Sectioning, IMCL Staining, and Quantification:  
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Skeletal muscle sectioning and IMCL staining was performed on the TA 
muscles from KO or WT animals that were fed either HFD or CD (n=4; 2 male/2 
female).  Sectioning of the TA muscle, IMCL staining with the neutral lipid stain 
BODIPY, and quantification were performed as previously described (97, 189). 
Skeletal Muscle Mitochondrial Isolation:  
Mitochondria were isolated according to previously described methods 
with slight modifications (59).  Quadriceps muscles were collected and 
immediately placed in ice-cold PBS supplemented with 10mM EDTA.  
Connective tissue was removed and muscles were minced with scissors while 
incubating in PBS/EDTA 0.05% trypsin for 30 min. Muscles were then 
homogenized using a 30ml glass/Teflon potter Elvehjem tissue grinder in 
isolation buffer 1 (IBm1) containing 67mM mannitol, 50mM Tris/HCl, 1mM 
EDTA, and 1mg/ml BSA (pH 7.4). The homogenate was transferred to a conical 
tube and centrifuged at 700g for 10 minutes at 4°C.  The supernatant was 
transferred and centrifuged at 8,000g for 10 minutes at 4°C. The pellet was re-
suspended in a second isolation buffer (IBm2) containing 300mM mannitol, 
10mM Tris/HCl, and 3mM EGTA/Tris, then centrifuged at 8,000g for 10 minutes 
at 4°C. The resulting supernatant was discarded. Then the pellet was resuspended 
in 50 µl of respiration buffer (125mM KCl, 2mM K2PO4, 10mM HEPES, 1mM 
MgCl, 0.1mM EGTA, 1%BSA) for mitochondrial respiration measures. The 
protein concentration of the pellet was determined using the Pierce BCA protein 
assay.  
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Mitochondrial Oxygen Consumption Measures: 
 Oxygen consumption was measured polarographically using an Oxytherm 
(Hansatech) as previously described (65).  Freshly isolated mitochondria 
(~200µg) from each group were placed in the calibrated electrode chamber 
containing 500µl respiration buffer for basal respiration, 30(M palmitoyl-Coa 
supplemented with 2mM carnitine for state 2 respiration, 300(M ADP for state 3 
respiration, 0.5mM glutamate/0.025mM malate for state 3b respiration, 40(M 
oligomycin (Calbiochem) to induce state 4 respiration, and finally 200nM FCCP 
to induce state 5 respiration. This was repeated up to six times for each sample. 
Oxygen consumption rates were then normalized to mitochondrial protein content.  
Statistical Analysis: 
The experimental design outlined for this study consisted of two 
independent variables, each with two levels.  The independent variables were 
tamoxifen induced Cre mediated recombination of Brca1 (WT or KO) and diet 
(CD or HFD).  For GTTs, ITTs, endurance exercise test, IMCL, and 
mitochondrial function measures statistical analysis was performed using a two-
way ANOVA for non-repeated measures.  If a significant F ratio was found, 
Student-Newman-Keuls post-hoc analysis was used (see statistical outputs; 
Appendix B).  Due to an un-balanced design (a result of unexplained loss of 
animals) Acc kinetics, Ampk-p values and in situ fatigue were statistically 
analyzed using either a one-way, paired T-test (in situ muscle fatigued 
gastrocnemius vs. sedentary limb) or a one-way, non-paired T-test (comparing 
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across treatments).  Statistical significance was accepted at an & level of P%0.05.  
All analysis was completed with Sigma Stat statistical software (Systat software, 
Inc. San Jose, CA.) 
RESULTS: 
Anatomical Characteristics: Kyphosis was apparent to varying degrees only in 
the female KO+CD mice compared to WT+CD (Figure 5.2A,B) with the HFD 
appearing to attenuate this effect (Figure 5.2C).  Kyphosis was not readily 
apparent in male KO mice (Figure 5.2D,E,F).  Liver and visceral fat (VF) mass 
was elevated in WT+HFD female mice compared to WT+CD and KO+HFD 
(Table 5.1).  Heart mass/BW was greater in KO+CD and KO+HFD compared to 
WT+CD and WT+HFD female mice (Table 5.1).  In male mice, VF and liver 
mass were elevated in WT+HFD male mice compared to WT+CD (Table 5.2).  In 
addition, gastrocnemius muscle mass was elevated in KO+CD male mice 
compared to WT+CD (Table 5.2).  Male WT+HFD mice exhibited lower heart 
mass/BW compared to WT+CD mice (Table 5.2).  Further, Male KO+HFD mice 
presented with lower liver mass/BW and VF mass/BW compared to WT+HFD 
male mice (Table 5.2). However, liver mass/BW was lower in KO+CD compared 
to KO+HFD male mice (Table 5.2).  In WT+HFD mice VF mass/BW was 
elevated compared to WT+CD male mice (Table 5.2).   VF mass/BW was lower 
in KO+CD mice compared to KO+HFD male mice (Table 5.2).  Body weight 
change from baseline was greater in WT+HFD mice beginning after 6 weeks of 
HFD compared to all other groups (Figure 5.3A).  The increase in body weight 
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effect was not due to greater food intake in WT+HFD mice with KO mice 
consuming more calories per day regardless of diet (Figure 5.3B).  
Skeletal muscle functional capacity:  To determine if loss of Brca1 in skeletal 
muscle resulted in adverse effects in overall functional capacity we performed 
treadmill testing.  A main effect was detected for KO mice in total distance run 
compared to WT mice (Figure 5.4A).  Maximal speed was significantly lower in 
WT+HFD and KO+CD mice compared to WT+CD mice (Figure 5.4B).  In 
response to repetitive in situ contractions, WT+CD mice exhibited a significantly 
higher rate of decline at 1 min compared to KO, however no differences were 
detected after 5-mins of stimulation across all groups  (Figure 5.4C).  No 
significant differences in absolute tetanic force or specific force were detected 
across groups (Figure 5.4D).   
Glucose Tolerance Testing: To determine if loss of functional Brca1 in skeletal 
muscle altered glucose tolerance, overnight fasted GTTs were performed in WT 
and KO groups. No differences in basal glucose levels were detected across 
groups, however WT+HFD mice presented with significantly higher blood 
glucose at all times points post injection compared to WT+CD mice and 
KO+HFD mice (Figure 5.5A). In addition, the area under the curve (AUC) was 
also significantly elevated in the WT+HFD mice compared to all groups (Figure 
5.5B).   
Insulin Tolerance Testing: ITTs were utilized as a means to assess if loss of 
Brca1 resulted in altered peripheral insulin sensitivity.  Baseline blood glucose 
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levels in non-fasted mice prior to the insulin tolerance test were significantly 
higher in KO+HFD mice compared to KO+CD mice (Figure 5.6A).  In response 
to the insulin injection there was a main effect of genotype at 120min post insulin 
injection where blood glucose levels were elevated in WT mice compared to KO 
mice (Figure 5.6B).  At 30 and 120min post insulin injection blood glucose levels 
for both WT+CD and KO+HFD mice were lower compared to WT+HFD mice 
(Figure 5.6B). 
Intramuscular Lipid Content: IMCL content was assessed in cross sections of 
the TA muscle using the neutral lipid stain, BODIPY.  Significant main effects on 
IMCL content were detected for both diet and genotype (Figure 5.7A,B).  
Specifically, animals on a HFD exhibited elevated IMCL content, while the KO 
mice had significantly less IMCL content.  Within groups, IMCL content was 
greater in WT+HFD mice compared to WT+CD and KO+HFD mice (Figure 
5.7A,B).  Similarly, IMCL in KO+HFD mice was greater than KO+CD (Figure 
5.7A,B).  
Mitochondrial Function: In order to determine if the detected metabolic 
alterations were due to changes in mitochondrial function we measured 
mitochondrial OCR in isolated mitochondria.  A main effect was detected in 
mitochondrial OCR during basal and state 3 conditions with mitochondria isolated 
from KO mice having lower OCR compared to WT (Figure 5.8).  Further, under 
basal conditions a trend (P=0.14) was detected within the WT group where HFD 
resulted in elevated mitochondrial OCR (Figure 5.8).  In addition, a trend 
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(P=0.08) was detected with WT+HFD mice exhibiting greater mitochondrial 
OCR under basal conditions compared to KO+HFD (Figure 5.8).  No significant 
differences were detected in mitochondrial OCR during state 3b or 4 respiration 
(Figure 5.8). During state 5 respiration, a main effect of diet was detected with 
HFD presenting with greater mitochondrial OCR compared to CD mice (Figure 
5.8).  Further, under state 5 respiration conditions WT+HFD mice exhibited 
significantly greater OCR compared to WT+CD mice. (Figure 5.8). 
Contraction Induced Acc phosphorylation: We previously found that BRCA1 
directly bound to ACC in response to an acute bout of exercise (96).  Thus, we 
sought to determine if loss of Brca1 altered the phosphorylation status of Acc in 
response to muscle contraction. Contraction resulted in increases in gastrocnemius 
Acc-p in WT+CD and WT+HFD mice (Figure 5.9A).  No significant differences 
were detected in gastrocnemius Acc-p levels in KO+CD or KO+HFD mice in 
response to contraction (Figure 5.9A).  In KO+CD gastrocnemius muscles basal 
Acc-p levels were higher compared to WT+CD levels (Figure 5.9A).  However, 
Acc-p percent increase in response to contraction was significantly lower in 
KO+CD mice compared to WT+CD (Figure 5.9B).   
Contraction-Induced Ampk phosphorylation: ACC is a known substrate of 
AMPK, thus AMPK phosphorylation was assessed as a surrogate of upstream 
regulation of ACC.  Similar to Acc-p, Ampk-p levels were significantly greater in 
WT+CD and WT+HFD mice in response to contraction (Figure 5.10A).  However, 
contraction did not result in increased Ampk-p levels in KO mice (Figure 5.10A).  
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The percent increase in response to skeletal muscle contraction was significantly 
lower in KO+CD mice compared to WT+CD mice (Figure 5.10B).   
DISCUSSION: 
Previously, we identified BRCA1 as a novel regulator of lipid metabolism in 
adult skeletal muscle (96).  Here, we determined that loss of Brca1 in skeletal 
muscle of adult mice results in lower exercise tolerance coupled with lower 
mitochondrial function. Surprisingly, deletion of Brca1 in skeletal muscle of adult 
mice prevented HFD-induced gains in BW and VF mass.  In contrast to our 
previous results in cultured myotubes, in vivo loss of functional Brca1 in skeletal 
muscle attenuated the onset of HFD-induced insulin resistance and glucose 
intolerance.  Lastly, loss of Brca1 resulted in greater phosphorylation of Acc, but 
attenuated the ability of fatiguing contractions to induce increases in the 
phosphorylation content of Acc or Ampk.  Overall, these data clearly demonstrate 
that loss of Brca1 specifically in skeletal muscle leads to a complex and multi-
faceted phenotype in mice. 
 Brca1 has been described as a cell cycle regulator in multiple tissues, 
including murine immortalized skeletal muscle myoblasts (C2C12) (109).  The 
importance of Brca1 as a critical cell cycle regulator is well established, as 
overexpression of Brca1 in non-muscle cells results in embryonic lethality in mice 
due to cell cycle arrest (208).   In C2C12 myoblasts, Brca1 expression increases 
during differentiation suggesting that Brca1 plays an inhibitory role in the cell 
cycle of proliferating myoblasts (109).  Beyond this one correlative finding, the 
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role of Brca1 in skeletal muscle has been largely unexplored.  Based on these 
studies that demonstrate Brca1 is expressed in adult skeletal muscle, we 
hypothesize that Brca1 plays a major functional role in the regulation of muscle 
physiology (96, 109).  
Our data demonstrate that Brca1 expression is critical for maintenance of 
exercise tolerance.  Specifically, during exercise testing Brca1 KO mice ran 
shorter distances and were unable to achieve similar maximal exercise speeds 
compared to WT mice on a normal chow diet.  However, the Brca1 KO mice 
appear to exhibit protection from fatiguing in situ contractions during the early 
phases of stimulation with the protection lost over time.  Thus, loss of Brca1 
specifically in skeletal muscle appears to compromise overall function of the 
animal, however the exercise intolerance may not be due to increased muscle 
fatigue susceptibility.  Previous publications have shown that ablation of gene 
targets specifically in skeletal muscle results in similar phenotypes.  Interestingly, 
these genes often directly contribute to mitochondrial function and/or substrate 
metabolism.  For example, loss of PGC1& in skeletal muscle, a critical regulator 
of mitochondrial function, results in impaired exercise tolerance (78).  Further, 
rendering Ampk inactive also results in exercise intolerance in mice due to 
significant alterations in metabolic function (155).  In similar fashion, the loss of 
functional Brca1 in skeletal muscle resulted in exercise intolerance that was 
coupled with altered metabolic and/or mitochondrial function compared to WT 
mice.   
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Brca1 KO mice exhibit lower skeletal muscle mitochondrial function 
compared to the WT mice regardless of diet.  These metabolic alterations suggest 
that Brca1 expression impacts the overall phenotype of the skeletal muscle by 
affecting mitochondrial function.  Brca1 is known to localize to the mitochondria 
in various cell types, including MCF7 breast carcinoma cells (37, 131).  In the 
mitochondria Brca1 functions as a mtDNA repair protein, thereby playing a 
critical role in mitochondrial function since mtDNA encodes for a significant 
portion of mitochondrial proteins (131).  Previous results have shown that 
increases in mtDNA mutations and/or damage corresponds with impaired 
mitochondrial function in skeletal muscle (168, 228).  Therefore, it is logical to 
hypothesize that loss of functional Brca1 in skeletal muscle may impair 
mitochondrial function due to a decreased ability to repair damaged mtDNA.  
Similar effects occur with the loss of Brca1 in cardiac tissue, which results in 
decreased mitochondrial biogenesis and function (181).   Collectively, it is 
evident that Brca1 is required for optimal mitochondrial function in skeletal 
muscle.   
Chronic HFD consumption results in elevated IMCL accumulation that often 
corresponds with glucose intolerance and insulin resistance (121, 229).  In Brca1 
KO mice IMCL content associated with chronic HFD feeding was lower 
compared to WT+HFD mice.  Brca1 KO+HFD mice also exhibited greater 
glucose tolerance and insulin sensitivity compared to WT+HFD mice.  In fact, 
Brca1 KO+HFD mice exhibited glucose and insulin tolerance testing responses 
similar to WT and KO+CD mice.  These data suggest that loss of Brca1 
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attenuated the negative metabolic responses commonly associated with HFD 
consumption.  Although the protection of the KO mice from a HFD is surprising 
when considering the compromised mitochondrial function there is precedence 
for similar results in the literature.  For example, in other models where lipid 
oxidation mechanisms are impaired within the mitochondria, glucose reliance 
becomes elevated resulting in an increase in insulin sensitivity (107). Therefore, it 
is possible that chronic in vivo deletion of Brca1 induces an adaptation resulting 
in enhanced dependence on glucose as a substrate and as a result improved insulin 
sensitivity.  
 Brca1 KO mice exhibited lower IMCL content in response to HFD 
compared to WT mice despite KO mice consuming more calories per day 
independent of diet. Typically exposure of rodents to a HFD is associated with 
higher IMCL content with reduced mitochondrial function, however the KO 
animals exhibited lower IMCL and mitochondrial dysfunction.  It is plausible that 
the KO mice exposed to a HFD are shunting the excess lipid away from the 
muscle towards the liver, as there were elevations in the normalized liver mass.  
However, this effect is specific to the male mice, thus further experiments will be 
necessary to truly elucidate this effect.  A similar effect has been observed in mice 
lacking the critical plasma membrane lipid translocase, CD36/FAT (70).  
Specifically, the CD36-/- mice exhibit lower skeletal muscle uptake of circulating 
lipids, improved glucose tolerance and insulin sensitivity as well as reduced 
IMCL content (70).  Therefore, one possible explanation for the lower IMCL 
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content in Brca1 KO mice fed a HFD is that lipid delivery into skeletal muscle 
was reduced in Brca1 KO mice.  
  Acetyl CoA carboxylase functions as an important intracellular regulator 
of lipid metabolism in skeletal muscle (160, 213).  Our previous investigation 
reported an interaction between Brca1 and Acc-p which was thought to increase 
LCFA entry into the mitochondria by maintaining Acc-p levels (96).  However, 
this same study also demonstrated that acute decreases in BRCA1 expression 
resulted in elevated ROS production which was associated with increased 
phosphorylation levels of AMPK and ACC (96).  In agreement with our previous 
results, basal Acc-p levels were elevated in basal KO+CD mice compared to WT, 
however no significant activation of Ampk (upstream regulator) was seen in the 
Brca1 KO mice.  Previous research has demonstrated that phosphorylation of Acc, 
in some cases, can occur independent of Ampk activation (51, 77). In response to 
in situ muscle contractions there was no increase in phosphorylation of either 
Ampk or Acc in the KO mice suggesting that further increases in phosphorylation 
content is dependent upon Brca1.  However, it is possible that the lack of a 
contraction response is because phosphorylation status is at a maximal level under 
basal conditions in KO mice.  These data collectively suggest that the 
mitochondria in the KO mice are permissive to LCFA entry, however, the reduced 
mitochondrial function suggests that complete fatty acid oxidation is likely not 
occurring.    
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 The in vivo effects of loss of functional Brca1 in skeletal muscle contrast 
some of our previous findings where we induced acute decreases in BRCA1 
expression in cultured human myotubes (96).  We hypothesize that our data 
indicate differential consequences of acute versus chronic loss of Brca1.  As a 
result, the contrast in results may be due to an adaptation response from prolonged 
in vivo loss of Brca1 in the mouse model.  It is not unreasonable to speculate that 
our data indicate that prolonged loss of Brca1 in skeletal muscle induces a fiber 
type switching effect towards a more glycolytic and less oxidative muscle type.  
Similar responses have been seen with deletion of the &1 subunit of Ampk which 
significantly altered the muscle fiber type composition (165).  However, in 
preliminary analyses when assessing fiber type by myosin heavy chain expression 
we did not observe a clear shift in fiber type of the TA muscle (data not shown).  
It is possible that the observed effect is specific to the metabolic aspects of the 
muscle and the loss of Brca1 has little effect on the contractile phenotype of the 
muscle.  Therefore, the observed shift in metabolic phenotype associated with 
Brca1 KO is a plausible explination underlying the elevated glycolytic phenotype 
observed in Brca1 KO mice.  
 BRCA1 mutations resulting in partial or complete deletion of BRCA1 in 
humans are known to exist (82, 142), with little to no information regarding the 
peripheral consequences of the whole body BRCA1 mutations in humans being 
reported.  Although whole body BRCA1 mutations in women are frequently 
associated with an increased risk of tumorigenesis our data suggests skeletal 
muscle is another likely target for alterations in function due to the mutation.  For 
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example, women with BRCA1 mutations may have reduced exercise capacity 
and/or alterations in skeletal muscle metabolic function resulting in a more 
glycolytic skeletal muscle phenotype similar to what we observed in our mouse 
model.  Life-long loss of functional BRCA1 in women may induce lipid 
metabolism impairments in skeletal muscle resulting in elevated lipid storage in 
other organ systems within the body, including the liver and visceral fat pad.  
Consequences such as these may unknowingly be altering overall health in 
women with BRCA1 mutations.   
Collectively, these data demonstrate for the first time that Brca1 is as an 
important regulator of skeletal muscle function.  Surprisingly, deletion of Brca1 
protected mice from developing the metabolic consequences commonly 
associated with a HFD.  These results are intriguing on multiple levels and may 
suggest that Brca1 is a target to treat metabolic diseases, however deletion of 
Brca1 did result in negative functional consequences suggesting that is endeavor 
is unlikely.  Thus, it is clear that more research will be required to fully elucidate 
the underlying mechanisms responsible for the phenotype associated with loss of 










Figure 5.1 (A-E): Development of an inducible skeletal muscle BRCA1 knockout 
(HSA-Brca1-KO) mouse. (A) HSA-Cre-Brca1 Flox breeding scheme (B) Western 
blot verifying the presence of Mer-Cre-Mer (112kDa) in the gastrocnemius 
muscle of the HSA-Brca1-KO mice (C) schematic representation of the Flox site 
recombination after injection (D) DNA analysis of recombined amplicon in 
injected male and female mice (621bp band) compared to control (vehicle only) 
injected mice (no band).  (E) Brca1 recombined amplicon in injected mice was 




Figure 5.2 (A-F). Brca1 KO+CD mice exhibit kyphosis which is partially 
attenuated in response to HFD. Images of female (A) wild type (WT), (B) Brca1 
knockout (KO) control diet (CD), and (C) KO high fat diet (HFD) mice and a 
matching x-ray (below).  Loss of functional Brca1 in skeletal muscle results in the 
appearance of kyphosis in female mice consuming CD.  Kyphosis was not as 
apparent in female KO mice consuming HFD.  (D,E,F) Kyphosis was not 




Figure 5.3 (A-B). Loss of functional Brca1 in skeletal muscle prevents HFD-
induced increases in body weight. (A) WT and KO mice were placed on CD or 
HFD for 10 weeks.  After 6 weeks of feeding WT+HFD mice had significantly 
greater body weight compared to WT+CD (*P" 0.05) and KO+HFD (#P" 0.05) 
mice. (n=7-10mice/group) (B) Average daily feed intake did not differ across 
groups. A main effect was detected between WT and KO animals where KO 




Figure 5.4 (A-D). Deletion of Brca1 alters functional capacity of the skeletal 
muscle (A) A main effect in endurance exercise capacity was detected with KO 
mice exhibiting shorter distance compared to WT (P" 0.05). (B) Maximal 
exercise speed was lower in WT+HFD mice and in CD+KO mice compared to 
WT+CD mice (*P" 0.05).  (C) Force output over time during fatiguing muscle 
contractions.  After 1 minute of stimulated contractions the gastrocnemius muscle 
force production was lower in WT+CD mice compared to KO+CD mice (*P" 
0.05) when normalized to baseline force production.  At 5 minutes of contraction 
no significant differences between groups were detected. (D) No differences in 





Figure 5.5 (A-B). Deletion of Brca1 prevents HFD-induced glucose intolerance.  
(A) No significant differences in blood glucose levels were detected across groups 
at baseline.   After glucose injection blood glucose levels were higher in 
WT+HFD mice compared to WT+CD mice at 30, 60, 90 and 120min after 
glucose injection (*P"0.05).  WT+HFD blood glucose levels were greater than 
KO+HFD at 30, 60, 90, and 120min post glucose injection (#P"0.05) (B) Total 
AUC was greater in WT+HFD mice compared to WT+CD mice (*P"0.05), and 
KO+HFD mice (#P"0.05).  No significant differences were detected between WT 




Figure 5.6.  (A-B) Loss of Brca1 enhances insulin sensitivity in HFD mice and in 
control mice. (A) Non-fasted, baseline blood glucose levels a main effect was 
detected for diet with HFD mice presenting with greater baseline blood glucose 
values. Baseline blood glucose levels were also greater in KO+HFD diet mice 
compared to KO+CD ($P"0.05). (B) A main effect of genotype was detected at 
120min after insulin injection was detected with lower blood glucose in KO mice 
compared to WT mice (P" 0.05).  At 30 and 120min after insulin injection blood 
glucose was higher in WT HFD compared to WT CD (*P"0.05) and KO HFD 




Figure 5.7 (A-B). HFD-induced IMCL accumulation is attenuated in response to 
loss of Brca1 in skeletal muscle (A) IMCL was significantly elevated in the 
tibialis anterior (TA) muscle in both the WT and KO+HFD treated mice 
compared to the WT and KO+CD mice. KO+HFD IMCL accumulation was 
lower compared to WT+HFD (*P"0.05 vs. WT+CD; #P % 0.05 vs. KO+CD; 
$ P"0.05 WT+HFD vs. KO+HFD)  (B)  Representative images of IMCL through 
BODIPY (green-493/503) staining of neutral lipid droplets and nuclei (DAPI-
blue) within skeletal muscle cross sections of the TA. (n=4mice/group; 50-60 




Figure 5.8. Loss of functional Brca1 impairs maximal skeletal muscle 
mitochondrial function. A main effect was detected in mitochondrial oxygen 
consumption rate during basal and state 3 conditions with mitochondria isolated 
from KO mice were lower compared to WT (P"0.05). No significant differences 
were detected in mitochondrial oxygen consumption rates during state 3b or 4 
respiration. During state 5 respiration a main effect of diet was detected with HFD 
presenting with greater mitochondrial oxygen uptake rates compared to CD mice 
(P" 0.05).  A significant difference was also detected between WT+CD and HFD 
mice with a greater oxygen consumption rate in mitochondria isolated from HFD 




Figure 5.9 (A-C). Loss of functional Brca1 in skeletal muscle increases basal 
Acc-p levels and prevents an increase in Acc-p levels in response to fatiguing 
muscle contractions. (B=basal; C=contraction) (A) In response to muscle 
contractions, Acc-p levels in WT+CD and HFD mice were increased (*P" 0.05) 
in the gastrocnemius muscle compared to the non-contracting gastrocnemius 
muscle from the same animal.  No increase in Acc-p levels was detected in KO 
mice in response to gastrocnemius muscle contractions. KO+CD+Basal Acc-p 
levels were greater than WT+CD+Basal (#P" 0.05) (B) Contraction-induced 
percent change in Acc-p was lower in KO + CD compared to WT + CD (*P" 
0.05). (n=5-6 mice/group). (C) Representative immunoblot is depicted for each 




Figure 5.10 (A-C). Loss of functional Brca1 in skeletal muscle prevents an 
increase in Ampk-p levels in response to fatiguing muscle contractions. (B=basal; 
C=contraction) (A) In response to muscle contractions, Ampk-p levels in WT+CD 
and HFD mice were increased (*P" 0.05) in the gastrocnemius muscle compared 
to the non contracting gastrocnemius muscle from the same animal.  No increase 
in Ampk-p levels was detected in KO mice in response to gastrocnemius muscle 
contractions. (B) Contraction-induced percent change in Ampk-p was lower in 
KO+CD compared to WT+CD (*P" 0.05). (n=5-6 mice/group). (C) 








Due to the magnitude of this study multiple limitations were encountered 
with regards to the experimental approach and as a result of assumptions made a 
priori during the study design.  This section will address some of the limitations 
encountered and list them from most impactful to least.   
Sex differences: Both males and females were included in this study in an 
attempt to fully elucidate the effects of Brca1 in skeletal muscle.  Surprisingly, 
ablation of Brca1 resulted in some unique sex-specific responses.  For example, 
skeletal muscle force production was lower in the male KO mice, but higher in 
the female KO mice when compared to WT mice. Unfortunately, due to a low 
number of animals it was not possible to explore these results in greater depth in 
this dissertation.  In addition, the female KO mice exhibited the onset of kyphosis, 
which was not apparent in the males.  Also, sex differences were seen in tissue 
mass (i.e. visceral fat), however in this case it was possible to present the data 
separately (Table 1&2).  To address these initial observations of sex-related 
differences, it will be necessary to repeat these experiments adding more males 
and females to these groups to allow for presentation of the sexes separately.   
Brca1 antibody performance: Although these methods had previously 
been optimized, we were forced to purchase new reagents (i.e. new lots) and we 
have been unable to achieve optimal antibody results utilizing these antibodies. 
Specifically, the most recently purchased antibody was derived from a different 
lot number and failed to meet our previously established criteria for quality 
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control.  Unfortunately, the majority of antibodies for Brca1 are human-specific 
and very few options are available for mouse tissue (four total).  Thus, we were 
not confident enough in these results to present them as a portion of this research 
study but they are included in Appendix 1.  
SUMMARY: 
 The studies conducted in this dissertation work have resulted in the 
identification of a novel regulatory protein, Brca1, in skeletal muscle.   The 
compilation of results from these studies demonstrates that Brca1 is a critical 
metabolic regulator in skeletal muscle.  The initial purpose of study one in this 
dissertation was to identify specific mechanisms responsible for the metabolic 
alterations in skeletal muscle that occur in response to loss of circulating 
estrogens.  In this study we demonstrated that loss of circulating estrogens 
resulted in elevated IMCL content which corresponded with alterations in acyl 
carnitine species and mitochondrial dysfunction.  The results from study one 
suggested that lipid mitochondrial transport was altered in response to loss of 
circulating estrogens, pinpointing a potential estrogen-sensitive mechanism 
underlying these results.  Therefore, we began searching for an estrogen-sensitive 
gene that was also a known regulator of some aspect of lipid metabolism.   
Breast cancer 1, early onset (BRCA1) is a well-established estrogen-
sensitive, human caretaker gene that is the blueprint for the protein breast cancer 
type 1 susceptibility protein (BRCA1/Brca1).   Recent evidence had suggested 
that Brca1 regulated lipid metabolism in breast carcinoma cells through an 
interaction with the widely recognized skeletal muscle lipid mediator, acetyl CoA 
! "%+!
carboxylase (Acc).  Thus, we sought to determine in study two if BRCA1 was 
present in skeletal muscle in an estrogen sensitive manner and if the interaction 
between BRCA1 and the phosphorylated form of Acc (Acc-p) was underlying the 
altered metabolic responses from loss of circulating estrogens.  In study two we 
determined that BRCA1 was expressed in both mouse and human skeletal muscle 
and to our surprise BRCA1 expression did not differ between males and females.  
Further, we determined that BRCA1 interacted with ACC-p in both mouse and 
human skeletal muscle suggesting that the protein-protein interaction promoted 
the phosphorylation status of ACC, thereby improving lipid metabolism during 
exercise.  In addition, we demonstrated that loss of BRCA1 in human myotubes 
resulted in impaired mitochondrial function, elevated IMCL content, decreased 
insulin sensitivity and elevated ROS production.  Collectively, the data in study 
two indicated that while BRCA1 was unlikely to explain our results in the OVX 
model, the data did suggest that Brca1 is a critical regulator of skeletal muscle 
metabolic function.  Therefore, the data in study two made a compelling argument 
for a research study to be performed in vivo in an effort to more thoroughly 
analyze BRCA1 as a physiological and metabolic regulator of skeletal muscle.  
Therefore, in study three, we developed a skeletal muscle-specific, Brca1 
inducible knockout mouse model to assess the physiological importance of Brca1 
in skeletal muscle.  We determined that chronic in vivo, as opposed to acute in 
vitro, loss of Brca1 in skeletal muscle resulted in multiple physiological and 
metabolic alterations.  Specifically, loss of functional Brca1 in skeletal muscle 
resulted in impaired endurance exercise tolerance compared to wild type mice. 
! "%"!
Considerable differences in metabolic function were also detected in response to 
loss of Brca1 in skeletal muscle including reduced IMCL content and improved 
glucose tolerance and insulin sensitivity in response to HFD.  However, loss of 
Brca1 resulted in impaired mitochondrial function, elevated basal Acc-p levels 
and attenuated the skeletal muscle contraction-induced increase in 
phosphorylation of Acc and Ampk.   Collectively, these studies, specifically study 
two and three, have provided insight into the previously undocumented role of 
Brca1 in skeletal muscle.  These findings may serve as the foundation for a 
considerable amount of future research endeavors to further elucidate the role of 
Brca1 in skeletal muscle.   
FUTURE DIRECTIONS: 
As discussed in the limitations section of this dissertation, sex-specific 
differences were detected in a number of measures and most notably in our force 
production measures.  Therefore, additional male and female animals have been 
injected with tamoxifen or control drug and placed on CD or HFD to be used for 
further force production measures.  Additional male and female animals used in 
this portion of the study will allow for males and females to be assessed 
individually to further characterize sex-specific differences associated with Brca1 
and force production in skeletal muscle.        
Given the variety of alterations detected in our mouse models as a 
consequence of the loss of functional Brca1 in skeletal muscle, one of the next 
goals of this study will be to perform microarray analysis.  Theoretically, we 
! "%#!
anticipate that microarray analyses will help to identify specific targets underlying 
the documented physiological changes associated with loss of Brca1 in skeletal 
muscle and provide more direction to our results as we pursue the mechanisms in 
greater detail. 
Finally, our initial investigation regarding the functional role of BRCA1 in 
human myotubes demonstrated that an acute decrease in BRCA1 expression 
resulted in elevated ROS production leading to further metabolic alterations in 
skeletal muscle.  Therefore, we attribute a significant portion of our findings in 
Brca1 KO mice to adaptations that resulted from chronic elevations in ROS 
production due to mitochondrial dysfunction, however this hypothesis will need 





























































































































































































Two Way Analysis of Variance Friday, July 26, 2013, 10:55:25 AM 
 
Data source: Data 1 in KCJ_Respiration measures 
 
General Linear Model 
 
Dependent Variable: Basal  
 
Normality Test: Passed (P > 0.050) 
 
Equal Variance Test: Passed (P = 0.168) 
 
Source of Variation  DF   SS   MS    F    P   
genotype 1 25.414 25.414 5.330 0.030  
diet 1 12.032 12.032 2.524 0.126  
genotype x diet 1 0.675 0.675 0.142 0.710  
Residual 23 109.663 4.768    
Total 26 148.092 5.696    
 
 
The difference in the mean values among the different levels of genotype is greater than would be 
expected by chance after allowing for effects of differences in diet.  There is a statistically 
significant difference (P = 0.030).  To isolate which group(s) differ from the others use a multiple 
comparison procedure. 
 
The difference in the mean values among the different levels of diet is not great enough to exclude 
the possibility that the difference is just due to random sampling variability after allowing for the 
effects of differences in genotype.  There is not a statistically significant difference (P = 0.126). 
 
The effect of different levels of genotype does not depend on what level of diet is present.  There 
is not a statistically significant interaction between genotype and diet.  (P = 0.710) 
 
Power of performed test with alpha = 0.0500:  for genotype : 0.506 
Power of performed test with alpha = 0.0500:  for diet : 0.207 
Power of performed test with alpha = 0.0500:  for genotype x diet : 0.0500 
 
Least square means for genotype :  
Group Mean SEM  
WT -5.483 0.550 
KO -3.498 0.661 
 
 
Least square means for diet :  
Group Mean SEM  
CD -3.807 0.575 
HFD -5.174 0.639 
 
 
Least square means for genotype x diet :  
Group Mean SEM  
WT x CD -4.638 0.728  
WT x HFD -6.328 0.825  
KO x CD -2.976 0.891  





All Pairwise Multiple Comparison Procedures (Student-Newman-Keuls Method) : 
 
Comparisons for factor: genotype 
Comparison Diff of Means p q P P<0.050  
KO vs. WT 1.986 2 3.265 0.030 Yes  
 
 
Comparisons for factor: diet 
Comparison Diff of Means p q P P<0.050  
CD vs. HFD 1.366 2 2.247 0.126 No  
 
 
Comparisons for factor: diet within WT 
Comparison Diff of Means p q P P<0.05  
CD vs. HFD 1.690 2 2.172 0.138 No  
 
 
Comparisons for factor: diet within KO 
Comparison Diff of Means p q P P<0.05  
CD vs. HFD 1.043 2 1.115 0.439 No  
 
 
Comparisons for factor: genotype within CD 
Comparison Diff of Means p q P P<0.05  
KO vs. WT 1.662 2 2.043 0.162 No  
 
 
Comparisons for factor: genotype within HFD 
Comparison Diff of Means p q P P<0.05  
KO vs. WT 2.309 2 2.554 0.084 No  
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Two Way Analysis of Variance Friday, July 26, 2013, 10:56:08 AM 
 
Data source: Data 1 in KCJ_Respiration measures 
 
General Linear Model 
 
Dependent Variable: State 3  
 
Normality Test: Passed (P > 0.050) 
 
Equal Variance Test: Passed (P = 0.393) 
 
Source of Variation  DF   SS   MS    F    P   
diet 1 3.401 3.401 0.498 0.487  
genotype 1 27.791 27.791 4.072 0.055  
diet x genotype 1 0.662 0.662 0.0970 0.758  
Residual 23 156.975 6.825    
Total 26 188.590 7.253    
 
 
The difference in the mean values among the different levels of diet is not great enough to exclude 
the possibility that the difference is just due to random sampling variability after allowing for the 
effects of differences in genotype.  There is not a statistically significant difference (P = 0.487). 
 
The difference in the mean values among the different levels of genotype is not great enough to 
exclude the possibility that the difference is just due to random sampling variability after allowing 
for the effects of differences in diet.  There is not a statistically significant difference (P = 0.055). 
 
The effect of different levels of diet does not depend on what level of genotype is present.  There 
is not a statistically significant interaction between diet and genotype.  (P = 0.758) 
 
Power of performed test with alpha = 0.0500:  for diet : 0.0500 
Power of performed test with alpha = 0.0500:  for genotype : 0.376 
Power of performed test with alpha = 0.0500:  for diet x genotype : 0.0500 
 
Least square means for diet :  
Group Mean SEM  
CD -6.297 0.688 
HFD -7.023 0.765 
 
 
Least square means for genotype :  
Group Mean SEM  
WT -7.698 0.658 
KO -5.622 0.791 
 
 
Least square means for diet x genotype :  
Group Mean SEM  
CD x WT -7.175 0.871  
CD x KO -5.419 1.067  
HFD x WT -8.222 0.987  





Two Way Analysis of Variance Friday, July 26, 2013, 10:56:39 AM 
 
Data source: Data 1 in KCJ_Respiration measures 
 
General Linear Model 
 
Dependent Variable: State 3b  
 
Normality Test: Failed (P = 0.024) 
 
Equal Variance Test: Passed (P = 0.563) 
 
Source of Variation  DF   SS   MS    F    P   
genotype 1 30.684 30.684 2.636 0.118  
diet 1 0.642 0.642 0.0551 0.816  
genotype x diet 1 0.458 0.458 0.0393 0.845  
Residual 23 267.718 11.640    
Total 26 299.023 11.501    
 
 
The difference in the mean values among the different levels of genotype is not great enough to 
exclude the possibility that the difference is just due to random sampling variability after allowing 
for the effects of differences in diet.  There is not a statistically significant difference (P = 0.118). 
 
The difference in the mean values among the different levels of diet is not great enough to exclude 
the possibility that the difference is just due to random sampling variability after allowing for the 
effects of differences in genotype.  There is not a statistically significant difference (P = 0.816). 
 
The effect of different levels of genotype does not depend on what level of diet is present.  There 
is not a statistically significant interaction between genotype and diet.  (P = 0.845) 
 
Power of performed test with alpha = 0.0500:  for genotype : 0.219 
Power of performed test with alpha = 0.0500:  for diet : 0.0500 
Power of performed test with alpha = 0.0500:  for genotype x diet : 0.0500 
 
Least square means for genotype :  
Group Mean SEM  
WT -8.971 0.860 
KO -6.789 1.033 
 
 
Least square means for diet :  
Group Mean SEM  
CD -8.038 0.899 
HFD -7.722 0.999 
 
 
Least square means for genotype x diet :  
Group Mean SEM  
WT x CD -8.996 1.137  
WT x HFD -8.947 1.290  
KO x CD -7.080 1.393  





Two Way Analysis of Variance Friday, July 26, 2013, 10:56:59 AM 
 
Data source: Data 1 in KCJ_Respiration measures 
 
General Linear Model 
 
Dependent Variable: State 4  
 
Normality Test: Failed (P = 0.011) 
 
Equal Variance Test: Passed (P = 0.219) 
 
Source of Variation  DF   SS   MS    F    P   
genotype 1 28.517 28.517 0.930 0.345  
diet 1 40.093 40.093 1.307 0.265  
genotype x diet 1 22.649 22.649 0.738 0.399  
Residual 23 705.604 30.678    
Total 26 792.561 30.483    
 
 
The difference in the mean values among the different levels of genotype is not great enough to 
exclude the possibility that the difference is just due to random sampling variability after allowing 
for the effects of differences in diet.  There is not a statistically significant difference (P = 0.345). 
 
The difference in the mean values among the different levels of diet is not great enough to exclude 
the possibility that the difference is just due to random sampling variability after allowing for the 
effects of differences in genotype.  There is not a statistically significant difference (P = 0.265). 
 
The effect of different levels of genotype does not depend on what level of diet is present.  There 
is not a statistically significant interaction between genotype and diet.  (P = 0.399) 
 
Power of performed test with alpha = 0.0500:  for genotype : 0.0500 
Power of performed test with alpha = 0.0500:  for diet : 0.0785 
Power of performed test with alpha = 0.0500:  for genotype x diet : 0.0500 
 
Least square means for genotype :  
Group Mean SEM  
WT -9.602 1.396 
KO -7.499 1.677 
 
 
Least square means for diet :  
Group Mean SEM  
CD -7.303 1.460 
HFD -9.797 1.622 
 
 
Least square means for genotype x diet :  
Group Mean SEM  
WT x CD -9.292 1.846  
WT x HFD -9.912 2.093  
KO x CD -5.314 2.261  





Two Way Analysis of Variance Friday, July 26, 2013, 10:57:26 AM 
 
Data source: Data 1 in KCJ_Respiration measures 
 
General Linear Model 
 
Dependent Variable: State 5  
 
Normality Test: Passed (P > 0.050) 
 
Equal Variance Test: Passed (P = 0.753) 
 
Source of Variation  DF   SS   MS    F    P   
genotype 1 64.878 64.878 0.859 0.364  
diet 1 392.552 392.552 5.198 0.032  
genotype x diet 1 10.856 10.856 0.144 0.708  
Residual 23 1736.816 75.514    
Total 26 2233.302 85.896    
 
 
The difference in the mean values among the different levels of genotype is not great enough to 
exclude the possibility that the difference is just due to random sampling variability after allowing 
for the effects of differences in diet.  There is not a statistically significant difference (P = 0.364). 
 
The difference in the mean values among the different levels of diet is greater than would be 
expected by chance after allowing for effects of differences in genotype.  There is a statistically 
significant difference (P = 0.032).  To isolate which group(s) differ from the others use a multiple 
comparison procedure. 
 
The effect of different levels of genotype does not depend on what level of diet is present.  There 
is not a statistically significant interaction between genotype and diet.  (P = 0.708) 
 
Power of performed test with alpha = 0.0500:  for genotype : 0.0500 
Power of performed test with alpha = 0.0500:  for diet : 0.493 
Power of performed test with alpha = 0.0500:  for genotype x diet : 0.0500 
 
Least square means for genotype :  
Group Mean SEM  
WT -28.285 2.190  
KO -25.112 2.631  
 
 
Least square means for diet :  
Group Mean SEM  
CD -22.796 2.290  
HFD -30.601 2.544  
 
 
Least square means for genotype x diet :  
Group Mean SEM  
WT x CD -23.734 2.897  
WT x HFD -32.836 3.284  
! ##%!
KO x CD -21.859 3.548  




All Pairwise Multiple Comparison Procedures (Student-Newman-Keuls Method) : 
 
Comparisons for factor: genotype 
Comparison Diff of Means p q P P<0.050  
KO vs. WT 3.173 2 1.311 0.364 No  
 
 
Comparisons for factor: diet 
Comparison Diff of Means p q P P<0.050  
CD vs. HFD 7.804 2 3.224 0.032 Yes  
 
 
Comparisons for factor: diet within WT 
Comparison Diff of Means p q P P<0.05  
CD vs. HFD 9.102 2 2.939 0.049 Yes  
 
 
Comparisons for factor: diet within KO 
Comparison Diff of Means p q P P<0.05  
CD vs. HFD 6.507 2 1.749 0.229 No  
 
 
Comparisons for factor: genotype within CD 
Comparison Diff of Means p q P P<0.05  
KO vs. WT 1.875 2 0.579 0.686 No  
 
 
Comparisons for factor: genotype within HFD 
Comparison Diff of Means p q P P<0.05  














































The current status of this research registration is:
Approved
Approved on: 01/24/2011
Tracking Number: 10-63 (E-849)
The BSO's comments on this research are: IBC approval on 13 January 2011 at ABSL1 for construction of transgenic mice by breeding.









Send email to: espen@umd.edu
5.
Project Title: The role of BRCA1 in lipid utilization by the skeletal muscle6.
Other Personnel working on Project: Katie Jackson, Lindsay Wohlers, Ana Valencia7.
Lab Building: 87 - Central Animal Resources Facility8.
Lab Room Number: 21289.
Department Chair Name: Brad Hatfield10.
Department Chair Email Address: bhatfiel@umd.edu
Send email to: bhatfiel@umd.edu
11.
Generation of transgenic animals by breeding
Species of animal: micea.
Are two transgenic (or knockout) mouse strains being bred to create a new strain?: Yesb.
Is a transgenic (or knockout) mouse strain being bred to a new background strain?: Noc.
Is the transgene under the control of a gamma-retroviral long terminal repeat (LTR)?: Nod.
12.
Registration https://www.des.umd.edu/apps/research/print.cfm?R=849
1 of 4 8/8/13 7:59 PM
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Is more than 50% of the genome of an exogenous eukaryotic virus from a single family present?: Noe.
Describe the expected unique characteristics of viable offspring: Obesityf.
Describe the precautions that will be taken to minimize the possibility that animals could escape confinement: Animals
will be maintained only in approved cages
g.




Biological safety cabinet: No
Is biological safety cabinet certified annually: No




Overview. Please briefly describe the experimental design, highlighting the recombinant DNA methodology used and/or the use of
infectious microorganisms if either are part of the study. Write for non-specialists and limit your response to 300 words. Do not cut and
paste from a grant application.
Our goal is develop a transgenic mouse where we can genetically ablate BRCA1 specifically from skeletal muscle in adult mice. Thus,
our model we be controlled through a drug-inducible gene strategy. In order to develop the model, we need to complete a breeding
strategy. We plan to breed male HSA-mER-Cre-mER (n=5) (hemizygous_obtained from Dr. Karyn Esser_University of Kentucky) with
female BRCA1 fl/fl (n=5) (obtained from NCI Mouse repository). Approximately 50 of the offspring will be HSA-BRCA fl/+. We will
then breed male HSA-BRCA fl/+ to female BRCA1 fl/fl to generate HSA-BRCA1fl/fl mice. All animals will be genotyped before use.
Genotyping will be done with a tail snip prior to 21 days of age. To induce ablation of BRCA1 in skeletal muscle from the
HSA-BRCA1fl/fl animals, we will treat animals with tamoxifen (T) for 5 consecutive days at (0.5mg/day_500µL IP). Control
HSA-BRCA1fl/fl animals will receive vehicle injections for 5 consecutive days (85 sunflower oil/15 ethanol mixture_500µL IP). After
5 days, animals will remain in their cages for 14 days to allow washout of the (T).
14.
Risk Assessment and Control. Please attach a brief protocol-specific risk assessment. Include consideration of parent and recombinant
agent pathogenicity, virulence, infectious dose, route of transmission, host range, and stability, as well as the likelihood of exposure and
consequences of exposure. How will identified risks be controlled (e.g. PPE, work practices, etc.)?
All animals will be handled with appropriate PPE, which includes lab coats, gloves, and eye protection. There is no pathogencity with
these animals and since the animals are transgenic there is not a likelihood of exposure.
15.
Responisble Conduct of Life Sciences Research
Will the intermediate or final product of your experiments:
Enhance the harmful consequences of the agent or toxin?
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clinical or agricultural justification?
Confer to the agent or toxin resistance to clinically or agriculturally useful prophylactic or
therapeutic interventions against that agent or toxin or facilitate their ability to evade
detection methodologies?
Increase the stability, transmissibility, or the ability to disseminate the agent or toxin?
Alter the host range or tropism of the agent or toxin?
Enhance the susceptibility of a host population to the agent or toxin?
Generate or reconstitute an eradicated or extinct agent or toxin?
After considering the above answers, do you believe there is the potential for your research data / product to be readily
utilized to cause public harm?
b.
For any question that was answered "yes" above, please provide sufficient information to allow for review of the indicated
concern:
c.
Researcher checked the box, "I confirm that I have carefully reviewed my proposed research for its potential to generate data /
product that could be readily utilized to cause public harm."
d.
Post-exposure procedures. Please describe post-exposure procedures that will be followed in the event of an accidental exposure.
Describe what first aid will be implemented: Exposure to the transgene is very unlikely, due to this being a transgenic mouse.
However, if an animal handler is bit or is somehow exposed to tissue from the animals. The area will be thoroughly cleaned through
washing with soap and water. In addition, the area with be cleaned with an aspectic agent. If this is due to animal bite, we will contact
the UMD Health Center for further directions.
Will medical follow-up be obtained? No
If yes, where?
Describe the reporting procedures after the exposure.
Note: Spills resulting in release or accidents involving rDNA must be reported to the BSO in compliance with the requirements of the
NIH Guidelines.
17.
Section of NIH Guidelines: III-E-318.
Containment: BL119.
Home | Topics | Forms | Documents | Training | Staff
Registration https://www.des.umd.edu/apps/research/print.cfm?R=849
3 of 4 8/8/13 7:59 PM
! #%(!
We would greatly appreciate your feedback about this site.
Copyright © 1996-2013 University of Maryland DES
 
UMD Home | Directories | Calendar
Maintained by Department of Environmental Safety
Direct questions and comments to safety@umd.edu
Registration https://www.des.umd.edu/apps/research/print.cfm?R=849




INSTITUTIONAL REVIEW BOARD 
0101 Lee Building 





Date:  October 29, 2010 
 
To:  Espen Spangenburg, PhD 
  Assistant Professor 
  Department of Kinesiology 
  University of Maryland College Park 
 
Cc:  Kathryn C. Jackson 
  Student 
  Department of Kinesiology 
  University of Maryland College Park 
 
From:  Joseph M. Smith, MA, CIM 
  IRB Manager 
University of Maryland, College Park 
 
Re:  Request for Human Subject Research Determination 
 
Title: “Is BRCA1 expressed in human skeletal muscle and does it play a role in 
regulating lipid metabolism?” 
 
The request for determination of Non Human Subject Research for the above-cited 
project has been reviewed by the University of Maryland College Park Institutional 
Review Board Office.  According to the information provided, it has been determined 
that this project does not meet one or both of the following definitions and therefore does 
not require further evaluation by the University of Maryland College Park Institutional 
Review Board. 
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If the scope of your project changes and meets one of the above definitions, an IRB 
protocol must be created and submitted to the UMCP IRB for approval.  For further 
clarification, questions or concerns please contact the IRB Office at 301-405-0678.   
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